has_age
The object is the elapsed time since birth of the subject.
has_intent
has_heart_disorder
has_neoplasm
has_age_at_pathology
has_age_at_diagnosis
has_age_at_start_rt
has_biological_sex
brings_about
Acts on or influences an entity.
has_disease
has_histology
has_finding
has_prescribed_radiation_dose
has_procedure
has_stage
has_survival
has_unit
has_vital_status
is_diagnosed_with
is_staged_with
temporally_related_to
Related in time by preceding, co-occuring with, or following.
follows
Occurs earlier in time. This includes antedates, comes before, is in advance of, predates, and is prior to.
is_adjuvant_to
precedes
co-occurs_with
Occurs at the same time as, together with, or jointly. This includes is co-incident with, is concurrent with, is contemporaneous with, accompanies, coexists with, and is concomitant with.
is_concurrent_with
is_neo_adjuvant_to
is_when
is_treated_in
Hospital or institute (range) where patient (domain) was treated.
associated_with
has a significant or salient relationship to.
has_person_identifier
conceptually_related_to
delineation_of
occurs_in
Takes place in or happens under given conditions, circumstances, or time periods, or in a given location or population. This includes appears in, transpires, comes about, is present in, and exists in.
has_occurrence
functionally_related_to
That part of a phenomenon which is directly observable or concretely or visibly expressed, or which gives evidence to the underlying process. This includes expression of, display of, and exhibition of.
has_organism_attribute
causes
brought_about_by
caused_by
spatially_related_to
location_of
The position, site, or region of an entity or the site of a process.
has_location
indicates
Gives evidence for the presence at some time of an entity or process.
indicated_by
uses
Employs in the carrying out of some activity. This includes applies, utilizes, employs, and avails.
used_by
diagnoses
Distinguishes or identifies the nature or characteristics of.
diagnosed_by
measures
Ascertains or marks the dimensions, quantity, degree, or capacity of.
measured_by
property_of
Characteristic of, or quality of.
has_property
measurement_of
The dimension, quantity, or capacity determined by measuring.
has_measurement
degree_of
has_degree
uses_ACE_inhibitor
has_performance_status
has_AJCC_version
has_body_mass_index
has_body_part
has_chemo_timing
has_count
has_fraction_count
has_image_count
has_patient_count
has_count_pet_5g
has_date
has_alive_last_checked_date
method_of
The manner and sequence of events in performing an act or procedure.
has_method
physically_related_to
part_of
Composes, with one or more other physical units, some larger whole. This includes component of, division of, portion of, fragment of, section of, and layer of.
has_part
has_cause_of_death
has_chemo_start_date
has_clinical_m_stage
has_clinical_n_stage
has_clinical_stage
has_clinical_t_stage
has_cumulative_dose
has_body_height
has_body_weight
has_date_of_death
has_date_of_diagnosis
has_date_of_procedure
has_death
has_death_finding
has_comorbidity
has_disease_date
has_disease_finding
has_disease_qualifier
has_dose
has_duration
has_dysphagia
has_dyspnea
has_fev1_percentage
has_fev1_test
has_version
has_fraction_dose
has_fractionation_part
has_hypertension
has_life
has_marital_status
has_max_esophagus_dose
has_mean_esophagus_dose
has_mean_lung_dose
has_modality
has_nodal_tumor_volume
has_overall_duration
has_pacs_patient
has_pacs_series
has_pacs_study
has_pathological_m_stage
has_pathological_n_stage
has_pathological_stage
has_pathological_t_stage
has_patient_finding
has_patient_guid
has_primary_tumor_volume
has_procedure_date
has_procedure_duration
has_qualifier
has_rt_dose
has_rt_end_date
has_rt_start_date
has_radiation_therapy
has_secondary_neoplasm
has_series
has_series_guid
has_series_uid
has_smoking_status
has_study
has_study_guid
has_study_uid
has_surgical_procedure
has_survival_time
has_tumor_burden
has_tumor_volume
has_uid
has_volume
has_date_observed
has_id
has_birth
has_recurrence_status
has_recurrence_time
has_chemo_end_date
has_laterality
process_of
Action, function, or state of.
has_process
manifestation_of
has_overall_stage
has_manifestation
result_of
The condition, product, or state occurring as a consequence, effect, or conclusion of an activity or process. This includes product of, effect of, sequel of, outcome of, culmination of, and completion of.
has_result
affects
Produces a direct effect on. Implied here is the altering or influencing of an existing condition, state, situation, or entity. This includes has a role in, alters, influences, predisposes, catalyzes, stimulates, regulates, depresses, impedes, enhances, contributes to, leads to, and modifies.
affected_by
manages
Administers, or contributes to the care of an individual or group of individuals.
managed_by
treats
Applies a remedy with the object of effecting a cure or managing a condition.
treated_by
complicates
Causes to become more severe or complex or results in adverse effects.
complicated_by
prevents
Stops, hinders or eliminates an action or condition.
prevented_by
disrupts
Alters or influences an already existing condition, state, or situation. Produces a negative effect on.
disrupted_by
performs
Executes, accomplishes, or achieves an activity.
performed_by
exhibits
Shows or demonstrates.
exhibited_by
produces
Brings forth, generates or creates. This includes yields, secretes, emits, biosynthesizes, generates, releases, discharges, and creates.
produced_by
practices
Performs habitually or customarily.
practiced_by
interacts_with
carries_out
Executes a function or performs a procedure or activity. This includes transacts, operates on, handles, and executes.
carried_out_by
contains
Holds or is the receptacle for fluids or other substances. This includes is filled with, holds, and is occupied by.
contained_in
consists_of
Is structurally made up of in whole or in part of some material or matter. This includes composed of, made of, and formed of.
connected_to
Directly attached to another physical unit as tendons are connected to muscles. This includes attached to and anchored to.
interconnects
Serves to link or join together two or more other physical units. This includes joins, links, conjoins, articulates, separates, and bridges.
branch_of
Arises from the division of. For example, the arborization of arteries.
tributary_of
Merges with. For example, the confluence of veins.
ingredient_of
Is a component of, as in a constituent of a preparation.
has_ingredient
has_tributary
interconnected_by
constitutes
has_branch
adjacent_to
Close to, near or abutting another physical unit with no other structure of the same kind intervening. This includes adjoins, abuts, is contiguous to, is juxtaposed, and is close to.
surrounds
Establishes the boundaries for, or defines the limits of another physical structure. This includes limits, bounds, confines, encloses, and circumscribes.
surrounded_by
traverses
Crosses or extends across another physical structure or area. This includes crosses over and crosses through.
traversed_by
conceptual_part_of
Conceptually a portion, division, or component of some larger whole.
has_conceptual_part
evaluation_of
Judgment of the value or degree of some attribute or process.
has_evaluation
assesses_effect_of
Analyzes the influence or consequences of the function or action of.
assessed_for_effect_by
issue_in
Is an issue in or a point of discussion, study, debate, or dispute.
has_issue
derivative_of
In chemistry, a substance structurally related to another or that can be made from the other substance. This is used only for structural relationships. This does not include functional relationships such as metabolite of, by product of, nor analog of.
has_derivative
developmental_form_of
An earlier stage in the individual maturation of.
has_developmental_form
analyzes
Studies or examines using established quantitative or qualitative methods.
analyzed_by
at_date_time
has_value
Palliative
Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.
Adjuvant Radiotherapy
Radiation therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence.
Great Blood Vessel
Any of the major arteries or veins attached to the cardiac atria or ventricles. This includes the aorta, superior and inferior vena cava and the pulmonary arteries and veins.
Narrow Surgical Margin
An indication that a surgical margin is in close proximity to the excised tumor.
Volume Modulated Arc Therapy
Radiation therapy delivered to the whole volume of target tissue by a single rotation of the linear accelerator gantry.
Scanning Proton Beam Therapy
Proton beam radiation therapy in which magnets deflect and steer the proton beam.
Scattering Proton Beam Therapy
Proton beam radiation therapy in which the proton beam is spread by placing scattering material in the path of the protons.
ECOG Performance Status
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
ECOG Performance Status 0
Fully active, able to carry on all pre-disease performance without restriction.
ECOG Performance Status 1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
ECOG Performance Status 2
Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
ECOG Performance Status 3
Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
ECOG Performance Status 4
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
ECOG Performance Status 5
Dead.
Tumor Regression Grade
TRG
A pathologic grading system used to evaluate the tumor response to preoperative chemotherapy and radiation.
FOLFOX Regimen
CF/5-FU/L-OHP
Fluorouracil/Leucovorin Calcium/Oxaliplatin
One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.
Percent Predicted Forced Expiratory Volume in 1 Second
Forced expiratory volume in one second as a proportion of the predicted normal value. (CDISC)
Dose Volume Histogram
A plot of a cumulative dose-volume frequency distribution that graphically summarizes the simulated radiation distribution within a volume of interest of a patient which would result from a proposed radiation treatment plan.
Gross Target Volume
The gross palpable or visible/demonstrable extent and location of malignant growth.
Low Anterior Resection
Resection of the rectum for cancer through an incision in the lower abdomen.
Grade X
A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.
4-Dimensional Conformal Radiation Therapy
3-Dimensional conformal radiation therapy that is designed to compensate for motion of the tumor and surrounding normal tissue during each treatment session.
4-Dimensional Computed Tomography
4DCT
RC-CT
Respiratory Correlated CT
Computed tomography scans designed to minimize motion artifacts. 4DCT can be accomplished by collecting data for the duration of the patient's respiratory cycle and by oversampling CT data acquisition at each slice.
Robot-Assisted Laparoscopic Surgery
A surgical technique that uses a specially designed robotic system to aid with a laparoscopic surgical procedure.
Oxaliplatin
Stereotactic Body Radiation Therapy
SBRT
Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.
Macroscopically Positive Surgical Margin
The presence of macroscopically visible residual tumor at the edge of a surgically excised specimen.
Grossly Negative and Microscopically Positive Surgical Margin
The presence of microscopically visible residual tumor at the edge of a surgically excised specimen that otherwise looks macroscopically normal.
Tumor Size
The size of a tumor in its greatest dimension.
Chemotherapy Regimen or Agent Combination
A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.
Upper Third of the Esophagus
Upper Esophagus
The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.
Middle Third of the Esophagus
Middle Esophagus
The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.
Lower Third of the Esophagus
Lower Esophagus
The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.
Pathologic Complete Response
Complete Pathological Response
pCR
The disappearance of all signs of cancer, supported by pathological examination.
Supratentorial Brain
The part of the brain above the tentorium cerebellum. (NCI) For most authors, this is the cerebral hemispheres plus the basal ganglia, but most clinicians do not include the basal ganglia.
4D PET Scan
4D Gated PET Scan
Positron emission tomography imaging collected over time. It is designed to capture the internal movement of organs and the metabolism of the tumor. It creates the most complete and accurate information on the tumor and provides information how the tumor moves with breathing and other body motions.
Vinorelbine
A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.
Carboplatin
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)
Epipodophyllotoxin Compound
An alkaloid isolated or derived synthetically from Podophyllum peltatum that can bind to and inhibit topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.
Stoma
A surgically created opening from an area inside the body to the outside.
Stage IA3
A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)
Paclitaxel
A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)
Occult Stage
A stage term that refers to a cancer in which the primary site is unknown (not detectable by clinical or radiologic examination). The definition of occult stage depends on the particular type of cancer that it refers to; for example, for breast cancer, occult stage is defined as cancer presenting with axillary lymph node metastasis without a primary in the breast being found; for non-small cell lung carcinoma, occult stage is defined as cancer detectable by sputum cytology only and the primary tumor is undetectable radiographically or during bronchoscopy.
Unresectable
Unable to be removed with surgery.
Moderately Differentiated
Describes tumor cells that have lost some of the appearance of normal cells. They tend to grow and spread at a faster rate than well differentiated tumor cells.
Poorly Differentiated
Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.
Well Differentiated
Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.
Woman
An adult, female human.
Man
An adult, male human.
Platinum Compound
A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.
Taxane Compound
A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.
Biopsy
The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.
Multimodality Therapy
Use of two or more simultaneous or consecutive treatment modalities; e.g., surgery + radiation, or radiation + immunotherapy. Does not refer to use of two or more chemotherapeutic agents.
Docetaxel
A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)
Laparotomy
Creation of a surgical opening into the abdominal cavity.
Lymphadenectomy
Lymph Node Dissection
Surgical removal of lymph nodes, usually done to assess the spread of cancer.
Pneumonectomy
The excision of part or all of a lung.
Radiation Therapy
Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.
Surgical Procedure
A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.
Stereotactic Radiosurgery
A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.
Adjuvant Chemotherapy
Chemotherapy that is administered subsequent to the main treatment plan to minimize or prevent disease recurrence.
Gamma Knife
A treatment using gamma rays, a type of high-energy radiation that can be tightly focused on small tumors or other lesions in the head or neck, so very little normal tissue receives radiation. The gamma rays are aimed at the tumor from many different angles at once, and deliver a large dose of radiation exactly to the tumor in one treatment session. This procedure is a type of stereotactic radiosurgery.
Chemotherapy
The use of synthetic or naturally-occurring chemicals for the treatment of diseases.
Fractionation
Dividing the total dose of radiation therapy into several smaller, equal doses delivered over a period of several days.
Thoracic Surgical Procedure
Surgery performed on the thoracic organs, most commonly the lungs and the heart.
Neoadjuvant Therapy
Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy.
Adjuvant Therapy
Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.
Maintenance Therapy
Continuation of treatment for an extended period of time to prevent relapse.
Treatment Regimen
Treatment Protocol
A treatment plan that specifies the dosage, the schedule, and the duration of treatment.
Laparoscopic Surgery
Surgery done with the aid of a laparoscope. A laparoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.
Follow-up
The activity of monitoring a person's health over time after treatment.
3-Dimensional Conformal Radiation Therapy
3D-CRT
A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.
Abdominal Surgical Procedure
Surgery performed on any part of the abdominal region of the body.
Intensity-Modulated Radiation Therapy
IMRT
An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.
Total Mesorectal Excision
TME
Surgery for rectal cancer involving precise removal of an intact mesorectal envelope with tumor-free margins. Associated with local recurrence rates below 5% in clinical trials.
Body Mass Index
A general indicator of the body fat an individual is carrying based upon the ratio of weight to height.
Comorbidity
The coexistence of two or more disease processes.
Data Source
The person or authoritative body who provided the information.
Female
A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.
Magnetic Resonance Imaging
Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.
Patient
A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.
Positron Emission Tomography
PET Scan
A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.
Computed Tomography
A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.
Cetuximab
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
Gender
The assemblage of properties that distinguish people on the basis of the societal roles expected for the two sexes.
Smoking Cessation
nicotine_stop
Discontinuation of the habit of smoking.
Blood Sample
A small volume of blood removed for testing or storage.
Capecitabine
Xeloda
Histologic Grade
The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.
Tumor Tissue
A tumor sample, or entire tumor that is removed for microscopic examination.
Diagnostic Procedure
Any procedure or test to diagnose a disease or disorder.
Raltitrexed
Tomudex
An anticancer drug that stops tumor cells from growing by blocking the ability of cells to make DNA. It belongs to the family of drugs called thymidylate synthase inhibitors.
Mitomycin
Mitomycin-C
A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations.
Clinics and Hospitals
Institutions with an organized medical staff for the medical care, treatment, and cure of the sick and wounded, for the study of disease, and for the training of physicians, nurses, and allied health personnel.
Tissue Sample
A piece of tissue removed from an organism for examination, analysis, or propagation.
Smoking Status
An indication of a person's current tobacco and nicotine consumption as well as some indication of smoking history.
Social Circumstances
A set of concepts that results from or is influenced by criteria or activities associated with the social environment of a person.
Male
A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.
Outcome
The result of an action.
Bevacizumab
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Performance Status
A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Temporal Qualifier
Terms used to indicate units of time or other terms associated with time.
ACE Inhibitor
Any substance that inhibits angiotensin-converting enzyme (ACE), an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.
Age
How long something has existed; elapsed time since birth.
Birth
The event of being born.
Date
The particular day, month and year an event has happened or will happen.
Laterality
Dominant use or manifestations of one side of the body versus the other; referring to a side of the body or of a structure.
Marital Status
A demographic parameter indicating a person's current conjugal status.
Person
A human being.
Weight
The vertical force exerted by a mass as a result of gravity.
Intervention or Procedure
An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.
Right
Being or located on or directed toward the side of the body to the east when facing north.
Left
Being or located on or directed toward the side of the body to the west when facing north.
Duration
The period of time during which something continues.
Length
The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.
Volume
The amount of three dimensional space occupied by an object or the capacity of a space or container.
Height
The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension.
Identifier
One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.
Zubrod Performance Status
A scale used to assess how a patient's disease is progressing and assess how the disease affects the daily living abilities of the patient.
Anal Margin
Anal Verge
The transitional zone between the moist, hairless, modified skin of the anal canal and the perianal skin.
Count
To determine the number or amount of something; the result of this activity.
Dose
A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.
Fraction
A part, a fragment of a whole.
Margin
A boundary line or the area immediately inside the boundary.
Percentage
A fraction or ratio with 100 understood as the denominator.
Postal Code
Any system designed to expedite the sorting and delivery of mail by assigning a series of alphanumeric codes to each delivery area. Also used to refer to any individual delivery area code.
Resectable
Capable of being removed by surgery.
Size
The physical magnitude of something.
Version
A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications.
Vital Status
The state or condition of being living or deceased; also includes the case where the vital status is unknown.
Intent
An anticipated outcome that is the purpose for actions taken, thus guiding the action.
Respiratory System Disorder
A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.
Non-Neoplastic Cardiovascular Disorder
A non-neoplastic disorder that affects the heart and/or vessels. Representative examples include myocardial infarction, endocarditis, arteriosclerosis, thrombosis, and lymphedema.
Stage I
Invasive cancer confined to the original anatomic site of growth without lymph node involvement.
Stage III
Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.
Stage IV
Cancer that has spread to distant anatomic sites beyond its original site of growth.
Stage IA
Invasive cancer confined to the original anatomic site of growth without lymph node involvement. The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)
Stage IB
Invasive cancer confined to the original anatomic site of growth without lymph node involvement. The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)
Stage IIIA
Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)
Stage IIIB
Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)
Stage IVA
Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)
Stage IVB
Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)
Stage IIIC
Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)
Stage IA1
A stage term referring to invasive cervical and lung cancer. For cervical cancer, it includes: T1a1, N0, M0. T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)
Stage IA2
A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0. T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)
Stage IIA
Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites. The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)
T1mi Stage Finding
A term that refers to a TNM finding of a primary tumor limited to the site of growth and indicates microinvasion only.
Stage IIB
Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites. The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)
Stage 0
Cancer confined to the epithelium without invasion of the basement membrane.
Stage II
Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.
Disease Grade Qualifier
A term that refers to the cellular differentiation of a malignant cellular infiltrate. A cancer is defined through grades I-IV (or 1-4), or as well, moderately, poorly differentiated or undifferentiated.
Grade 1
A morphologic qualifier indicating that a cancerous lesion is well differentiated.
Grade 2
A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.
Grade 3
A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.
Grade 4
A morphologic qualifier indicating that a cancerous lesion is undifferentiated.
Disease Treatment Qualifier
Disease Stage Qualifier
Tumor Burden
The total volume of all macroscopic tumor tumors in the body. It is the sum of the primary tumor, macroscopic lymph nodes metastases and distant metastases.
Sex
The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.
Adenocarcinoma
A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Death
The absence of life or state of being dead. (NCI)
Non-Small Cell Lung Carcinoma
A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.
Squamous Cell Carcinoma
A carcinoma arising from squamous epithelial cells. Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells. Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells. Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.
Cardiovascular Disorder
A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.
Diabetes Mellitus
A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.
Disease or Disorder
Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.
Endocrine System Disorder
A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.
Heart Disorder
A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.
Neoplasm
A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.
Finding
Clinical, laboratory or molecular evidence, or absence of evidence of disease.
Weight Loss
A reduction in total body weight.
Non-Neoplastic Respiratory Disorder
A non-neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, tracheitis, and tracheal agenesis.
Metastatic Malignant Neoplasm in the Lung
Lung Metastasis
The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.
Metastatic Malignant Neoplasm in the Bone
Bone Metastasis
The spread of a malignant neoplasm from a primary site to the skeletal system. The majority of metastatic neoplasms to the bone are carcinomas.
Distantly Metastatic Malignant Neoplasm
Distant Metastasis
A malignant tumor that has spread from its original (primary) site of growth to another site distant from the primary site.
Locally Metastatic Malignant Neoplasm
Regional Cancer
Refers to cancer that has grown beyond the original (primary) tumor to nearby lymph nodes or organs and tissues.
Secondary Neoplasm
A neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.
Metastatic Malignant Neoplasm
Metastasis
A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.
Cisplatin
An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.
Large Cell Carcinoma
A malignant epithelial neoplasm composed of large, atypical cells.
Site
A position in relation to its surroundings.
Life
The organic phenomenon that distinguishes living organisms from nonliving ones; showing characteristics of life.
Pulmonary Function Test
A broad range of tests that are performed to assess how well lungs inhale and exhale air and how efficiently they transfer oxygen into the blood.
Carbon Monoxide Diffusing Capability Test
DLCO
A measurement of carbon monoxide (CO) transfer from inspired gas to pulmonary capillary blood. During the test, the subject inspires a gas containing CO and one or more tracer gases to allow determination of the gas exchanging capability of the lungs.
Forced Expiratory Volume in 1 Second
A test of lung function, the FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. It is the most frequently used index for assessing bronchoconstriction or bronchodilatation.
Metastatic Malignant Neoplasm in the Brain
Brain Metastasis
A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).
Recurrent Disease
The return of a disease after a period of remission.
Molecular Abnormality
A molecular or cytogenic abnormality which occurs in either human disease states or disease models.
Small Cell Carcinoma
A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble "oat cells" under the microscope. Small cell carcinoma most often affects the lungs. Clinically, this is often a rapidly growing cancer that spreads to distant sites early.
No Evidence of Disease
Diagnostic tests fail to detect presence of disease.
BRAF Gene Mutation
Cyclophosphamide
A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Qualifier
A term that helps define and render a concept unique.
Surgical Margin
One of the criteria for assessment of the effectiveness of given surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. It is defined by the tissue plane through which the dissection has been done and the actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient. There are four types of surgical margins: intracapsular or intralesional, marginal, wide, and radical.
Adverse Event
Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).
KRAS Gene Mutation
Part
One of the portions into which something is regarded as divided and which together constitute a whole.
Doxorubicin
An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.
Circumferential Resection Margin
The distance between the radial extent of the tumor and the surgical incision used to excise the tumor. This distance is measured microscopically.
Male Gender
An individual who reports belonging to the cultural gender role distinction of male.
Female Gender
An individual who reports belonging to the cultural gender role distinction of female.
Neoplasm by Morphology
A classification system grouping neoplasms according to their cellular characteristics.
Metastatic Malignant Neoplasm in the Liver
Liver Metastasis
A malignant neoplasm that has spread to the liver from another (primary) anatomic site. Such malignant neoplasms may be carcinomas, lymphomas, melanomas, or sarcomas.
Lymphatic Invasion
A term referring to the presence of tumor emboli or tumor masses within lymphatic vessels.
Cancer TNM Finding
A cancer finding in the TNM system that is relevant to the diagnosis of cancer.
No Evidence of Metastatic Disease
Diagnostic tests fail to detect presence of metastatic lesions.
Positive Surgical Margin
Indicates the presence of tumor cells at the edge of a surgically excised specimen.
Negative Surgical Margin
Indicates the absence of tumor cells at the edge of a surgically excised specimen.
M0 Stage Finding
A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.
M1 Stage Finding
A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.
M1a Stage Finding
A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.
M1b Stage Finding
A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.
M1c Stage Finding
A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.
MX Stage Finding
A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.
N0 Stage Finding
A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis.
N1 Stage Finding
A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.
N3 Stage Finding
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes; for cutaneous melanoma it refers to metastases in 4 or more regional lymph nodes; for gastric cancer it refers to metastases in 7 or more regional lymph nodes; and for bladder cancer it refers to metastases in common iliac lymph nodes.
NX Stage Finding
A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.
T0 Stage Finding
A primary tumor TNM finding indicating that there is no evidence of primary tumor.
T1 Stage Finding
A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.
T1a Stage Finding
A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.1cm, but not more than 0.5 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is 4 cm or less in greatest dimension; and for thyroid cancer it refers to a primary tumor that is 1 cm or less in greatest dimension.
T1b Stage Finding
A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is more than 4 cm, but not more than 7 cm in greatest dimension; and for thyroid cancer it refers to a primary tumor that is more than 1 cm but not more than 2 cm in greatest dimension.
T1c Stage Finding
A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.
T2 Stage Finding
A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.
T2a Stage Finding
A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.
T2b Stage Finding
A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.
T2c Stage Finding
A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.
T3 Stage Finding
A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.
T4 Stage Finding
A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.
TX Stage Finding
A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.
Tis Stage Finding
A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.
Pathologic TNM Finding
TNM staging performed as part of pathologic specimen.
N2 Stage Finding
A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.
Generic TNM Finding
A cancer finding in the TNM system that is not specifically identified as a clinical, pathologic, recurrent (retreatment), or autopsy classification using an accepted prefix in accordance with TNM classification guidelines. Though the 6th Edition of the AJCC Cancer Staging Manual indicates that unspecified TNM staging descriptors may be considered synonymous with the corresponding fully specified clinical category, such omission may lead to ambiguity in meaning, and in practice unqualified descriptors are frequently used with other intended meanings. The generic TNM concepts in the NCI Thesaurus are intended to explicitly reflect this lack of specification.
Clinical TNM Finding
TNM staging performed with access to clinical information only.
Generic Distant Metastasis TNM Finding
Generic Regional Lymph Nodes TNM Finding
Generic Primary Tumor TNM Finding
Pathologic Distant Metastasis TNM Finding
Pathologic Regional Lymph Nodes TNM Finding
A pathologic finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to staging of regional lymph nodes.
Pathologic Primary Tumor TNM Finding
A pathologic finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to staging of the primary tumor.
Regional Lymph Node Dissection
Surgical removal of the lymph nodes located in a particular anatomic region. This procedure is commonly performed as a component of cancer staging.
Lobe of the Right Lung
One of the three lobes that comprise the right lung.
Lobe of the Left Lung
Either of the two (upper or lower) lobes that comprise the left lung.
Etoposide
A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)
Small Cell Lung Carcinoma
A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.
Therapeutic Procedure
An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.
Fluorouracil
5-FU
5-Fluorouracil
Medical Contraindication
A symptom or medical condition that makes a particular treatment or procedure inadvisable because a person is likely to have a bad reaction.
Disease Response
Response
The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.
Wedge Resection of Lung
Surgical removal of a wedge-shaped section of lung.
Married
Indicates a person currently joined in a legally binding matrimonial union. Classify common law marriage as married. Includes married couples living together and not living together.
Never Married
Indicates a person who has never been married or whose marriages have been annulled.
Widowed
Indicates a person who is no longer married because of the death of his/her spouse and has not remarried.
Divorced
Indicates a person whose marriage has been legally dissolved and has not remarried.
Separated
Indicates a person living apart from his/her spouse by legal arrangement.
Lymphocyte Count
The determination of the number of lymphocytes in a blood sample.
Adverse Event Attribution Category
A characteristic used to qualify the determination of whether an adverse event is related to medical product or procedure or related to the cancer or related to comorbidities.
Unrelated to Intervention
A characteristic used to qualify the adverse event as clearly not related to the medical intervention.
Unlikely Related to Intervention
A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.
Possibly Related to Intervention
A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.
Probably Related to Intervention
A characteristic used to qualify the adverse event as likely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to the medical intervention, unlikely to be attributed to concurrent disease or other medical interventions, and which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.
Definitely Related to Intervention
A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.
Domestic Partnership
Indicates a person who is a member of an unmarried couple, including same sex couples, living together in longstanding relationships, that are registered or unregistered.
Temporary
Not permanent; not lasting; lacking continuity or regularity.
Adverse Event by CTCAE Category
Adverse Event Associated with Pulmonary and Upper Respiratory Systems
Adverse Event Associated with the Gastrointestinal System
Adverse Event Associated with the Heart in General
Universally Unique Identifier
A 128 bit identifier. Depending on the mechanism used to generate it, it is either guaranteed to be different from all other UUIDs/GUIDs generated until 3400 AD or extremely likely to be different. Its relatively small size lends itself well to sorting, ordering, and hashing of all sorts, storing in databases, simple allocation, and ease of programming in general.
CTCAE Grade 1 Hypertension
Asymptomatic, transient (<24 hrs) increase by >20 mmHg (diastolic) or to >150/100 if previously WNL; intervention not indicated Pediatric: Asymptomatic, transient (<24 hrs) BP increase >ULN; intervention not indicated
CTCAE Grade 2 Hypertension
Recurrent or persistent (>=24 hrs) or symptomatic increase by >20 mmHg (diastolic) or to >150/100 if previously WNL; monotherapy may be indicated Pediatric: Recurrent or persistent (>=24 hrs) BP >ULN; monotherapy may be indicated
CTCAE Grade 3 Hypertension
Requiring more than one drug or more intensive therapy than previously Pediatric: Same as adult
CTCAE Grade 4 Hypertension
Life-threatening consequences (e.g., hypertensive crisis) Pediatric: Same as adult
CTCAE Grade 5 Hypertension
Hypertension Adverse Event
Recurrent Disease, Primary Site
Recurrence of symptoms of a disease at the original site.
Recurrent Disease, Distant Site
Recurrence of symptoms of a disease, at a site different and away from the original site.
CTCAE Grade 1 Dysphagia
Symptomatic, able to eat regular diet
CTCAE Grade 2 Dysphagia
Symptomatic and altered eating/swallowing (e.g., altered dietary habits, oral supplements); IV fluids indicated <24 hrs
CTCAE Grade 3 Dysphagia
Symptomatic and severely altered eating/swallowing (e.g., inadequate oral caloric or fluid intake); IV fluids, tube feedings, or TPN indicated >=24 hrs
CTCAE Grade 4 Dysphagia
Life-threatening consequences (e.g., obstruction, perforation)
CTCAE Grade 5 Dysphagia
Dysphagia Adverse Event
CTCAE Grade 1 Dyspnea
Dyspnea on exertion, but can walk 1 flight of stairs without stopping
CTCAE Grade 2 Dyspnea
Dyspnea on exertion but unable to walk 1 flight of stairs or 1 city block (0.1km) without stopping
CTCAE Grade 3 Dyspnea
Dyspnea with ADL.
CTCAE Grade 4 Dyspnea
Dyspnea at rest; intubation/ventilator indicated.
CTCAE Grade 5 Dyspnea
Death.
Dyspnea Adverse Event
Leucovorin Calcium
Calcium Folinate
Pemetrexed
A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.
Irinotecan
A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.
Prone Position
Prone
An anterior recumbent body position whereby the person lies on its stomach and faces downward.
Supine Position
Supine
A posterior recumbent body position whereby the person lies on its back and faces upward.
Cure
Serving or tending to restore health; a remedy.
Transanal Excision
Surgery for rectal cancer that spares the anus and leaves the sphincter intact. Surgery is performed through the anus and removes only the rectal tumor and small amounts of surrounding tissue.
Image Guided Radiation Therapy
IGRT
A procedure that uses a computer to create a picture of a tumor to help guide the radiation beam during radiation therapy. The pictures are made using CT, ultrasound, X-ray, or other imaging techniques. Image-guided radiation therapy makes radiation therapy more accurate and causes less damage to healthy tissue.
Tomotherapy
A type of external beam radiation therapy in which the radiation is delivered slice-by-slice, providing sequential delivery of radiation to different parts of the tumor. This method differs from other forms of radiation therapy in which the entire tumor volume is irradiated at one time.
FU-LV Regimen
Fluorouracil-Leucovorin Regimen
Mayo Clinic Regimen
Roswell Park Regimen
de Gramont Regimen
A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer. The Mayo Clinic regimen, Roswell Park regimen, and de Gramont regimen are different in the doses and times at which the two drugs are given.
Study
A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.
Chemotherapy Regimen Used to Treat Colorectal Carcinoma
FOLFIRI Regimen
FOLFIRI
Folinic Acid-Fluorouracil-Irinotecan Regimen
A chemotherapy regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan used in the treatment of advanced-stage and metastatic colorectal cancer.
XELOX regimen
XELOX
Xeloda-Oxaliplatin Regimen
Xeloda/Oxalipaltin
A regimen consisting of capecitabine and oxaliplatin used for the treatment of advanced stage colorectal cancer. This regimen differs from a similar regimen, CAPOX, with regards to the dosing schedule for oxaliplatin.
Inoperable
Not suitable for surgery.
Hemoglobin Measurement
A quantitative measurement of the amount of hemoglobin present in a sample.
Therapeutic Surgical Procedure
Never Smoker
A person who was not smoking at the time of the interview and has smoked less than 100 cigarettes in their life.
Non-Small Cell Carcinoma
A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.
Erlotinib
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
Gemcitabine
A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in "masked termination" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.
Proton Beam Radiation Therapy
A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.
Current Smoker
An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes. Includes daily smokers and non-daily smokers (also known as occasional smokers).
Former Smoker
A person who was not smoking at the time of the interview but has smoked at least 100 cigarettes in their life.
Conditionally Related to Intervention
A characteristic used to qualify the adverse event as unclassified in term of its relation to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to clinical event, including laboratory test abnormality, reported as an adverse reaction, about which more data is essential for a proper assessment or the additional data are under examination.
Relation to Intervention Unclassifiable
A characteristic used to qualify the adverse event as unclassifiable in term of its relation to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to an adverse reaction which cannot be judged because information about it is insufficient or contradictory, and cannot be supplemented or verified.
Radical
Directed to the root or source of a morbid process; to remove the root of a disease or all diseased tissue, as radical surgery.
Series Instance UID
A unique identifier for series of images.
Standardized Uptake Value
An effectively dimensionless measure of regional tracer uptake calculated as the activity concentration within a 2D region of interest (ROI) or 3D volume of interest (VOI) measured on a PET image (nCi1mL) / [injected dose (nCi) / body weight (g)].
Unique Identifier
A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data.
Biospecimen
Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.
Image Feature
In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.
Instance Unique Identifier
Data type unique identifier within a particular context.
Malignant Lung Neoplasm
A primary or metastatic malignant neoplasm involving the lung.
Pack Year
A quantification of lifetime tobacco exposure defined as (number of cigarettes smoked per day x number of years smoked)/20. One pack-year is smoking 20 cigarettes a day for one year.
Malignant Rectal Neoplasm
A primary or metastatic malignant neoplasm that affects the rectum. Representative examples include carcinoma, lymphoma, and sarcoma.
Malignant Rectosigmoid Neoplasm
A primary or metastatic malignant neoplasm that affects the rectosigmoid area. Representative examples include carcinoma, lymphoma, and sarcoma.
No Measurable or Evaluable Disease
Cause of Death
The circumstance or condition that results in the death of a living being.
Medical Record Number
An identifying number within an institution that is used to reference a subject's medical information.
Body Weight
The weight of a subject.
ALK Gene Mutation
Elapsed Time
The interval between two reference points in time.
Subject Identifier
Studynumber
A sequence of characters used to identify, name, or characterize the study subject.
Adverse Event by CTCAE v3 Severity Grade
Adverse Event by CTCAE v4 Severity Grade
Imaging Region of Interest
A specific area of interest defined by a sequence of image overlays or a sequence of contours described as a single point (for a point ROI) or more than one point (representing and open or closed polygon).
Teniposide
A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)
Abdominoperineal Resection
A therapeutic surgical procedure in which the anus, rectum, part of the sigmoid colon, and the regional lymph nodes are removed through abdominal and perineal incisions.
Vinblastine
A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)
Malignant Cervical Neoplasm
Primary or metastatic malignant neoplasm involving the cervix. --2003
Vinca Alkaloid Compound
A type of drug that blocks cell growth by stopping mitosis (cell division). Vinca alkaloids interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A vinca alkaloid is a type of mitotic inhibitor and a type of antimicrotubule agent.
Vincristine
A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)
Vindesine
A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)
Operable
Describes a condition that can be treated by surgery.
Sleeve Lobectomy
Surgery to remove a lung tumor in a lobe of the lung and a part of the main bronchus (airway). The ends of the bronchus are rejoined and any remaining lobes are reattached to the bronchus. This surgery is done to save part of the lung.
Metastasectomy
The surgical removal of metastases.
Stature
The height of a person while standing.
Tumor Volume
The size of a cancer measured by the amount of space taken up by the tumor. For example, the tumor volume of prostate cancer is the percentage of the prostate taken up by the tumor.
Chemoradiotherapy
Treatment that combines chemotherapy with radiation therapy
Absorbed Radiation Dose
The amount of energy from any type of ionizing radiation (e.g., alpha, beta, gamma, neutrons, etc.) deposited in any medium (e.g. water, tissue, air). This designates energy deposition by the radiation without regard to the type of matter or any biological considerations.
CyberKnife
A proprietary, robotic radiosurgery system designed to deliver precise beams of high dose radiation to tumors with extreme accuracy.
Prophylactic
In medicine, something that prevents or protects.
ERBB2 Gene Mutation
HER2 Gene Mutation
A molecular genetic abnormality indicating the presence of a mutation in the ERBB2 gene on chromosome 17q12.
AKT1 Gene Mutation
A change in the nucleotide sequence of the AKT1 gene.
EGFR Gene Mutation
A change in the nucleotide sequence of the EGFR gene.
Adverse Event by System Organ Class
Cough
A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.
Dysphagia
A disorder characterized by difficulty in swallowing.
Dyspnea
A disorder characterized by an uncomfortable sensation of difficulty breathing.
Esophageal stenosis
A disorder characterized by a narrowing of the lumen of the esophagus.
Gastrointestinal disorders
Grade 1 Cough
Mild symptoms; nonprescription intervention indicated
Grade 1 Dysphagia
Grade 1 Dyspnea
Shortness of breath with moderate exertion
Grade 1 Esophageal stenosis
Asymptomatic; clinical or diagnostic observations only; intervention not indicated
Grade 2 Cough
Moderate symptoms, medical intervention indicated; limiting instrumental ADL
Grade 2 Dysphagia
Symptomatic and altered eating/swallowing
Grade 2 Dyspnea
Shortness of breath with minimal exertion; limiting instrumental ADL
Grade 2 Esophageal stenosis
Symptomatic; altered GI function
Grade 3 Cough
Severe symptoms; limiting self care ADL
Grade 3 Dysphagia
Severely altered eating/swallowing; tube feeding or TPN or hospitalization indicated
Grade 3 Dyspnea
Shortness of breath at rest; limiting self care ADL
Grade 3 Esophageal stenosis
Severely altered GI function; tube feeding; hospitalization indicated; elective operative intervention indicated
Grade 4 Dysphagia
Life-threatening consequences; urgent intervention indicated
Grade 4 Dyspnea
Grade 4 Esophageal stenosis
Life-threatening consequences; urgent operative intervention indicated
Grade 5 Dysphagia
Grade 5 Dyspnea
Grade 5 Esophageal stenosis
Respiratory, thoracic and mediastinal disorders
Malignant neoplasm of rectosigmoid junction
Malignant neoplasm of rectum
Malignant neoplasm of bronchus and lung
Segmental resection of lung
Partial lobectomy
A segment resection removes a larger portion of the lung lobe than a wedge resection, but does not remove the whole lobe.
Lobectomy of Lung
Pulmonary lobectomy
A common surgical procedure that removes one lobe of the lung that contains cancerous cells.
Colostomy operation
The surgical creation or closure of an opening between the colon and the surface of the body.
Anterior resection of rectum
Permanent
Residual tumour status stages
The R classification, an auxiliary classification within the TNM system, denotes the absence or presence of residual tumor after treatment and describes residual tumor as macroscopic or microscopic in amount. The R classification considers residual tumor at the primary tumor siteThe R classification, an auxiliary classification within the TNM system, denotes the absence or presence of residual tumor after treatment and describes residual tumor as macroscopic or microscopic in amount. The R classification considers residual tumor at the primary tumor site, in the regional lymph nodes, and/or at distant sites. As such, it reflects the efficacy of primary treatment, influences the design and institution of additional therapy, and is a strong indicator of prognosis., in the regional lymph nodes, and/or at distant sites. As such, it reflects the efficacy of primary treatment, influences the design and institution of additional therapy, and is a strong indicator of prognosis.
Residual tumour stage RX
The presence of residual tumor cannot be assessed.
Residual tumour stage R0
No residual tumor.
Colostomy - stoma
Colostomy
A stoma to the colon.
Construction of temporary colostomy
The surgical creation of a temporary colostomy.
Construction of permanent colostomy
The surgical creation of a permanent colostomy.
Closure of colostomy
The surgical closure of a colostomy.
Residual tumour stage R1
Microscopic residual tumor.
Residual tumour stage R2
Macroscopic residual tumor.
Excision of lesion of rectum
Local excision
Saliva sample
Radiotherapy - preoperative control
The use of radiotherapy prior to the surgical removal of a tumor.
Radiotherapy - postoperative control
A postoperative course of radiotherapy.
Hartmann's procedure
Rectosigmoidectomy, closure of rectal stump and exteriorisation of bowel.
Organism
Generally, a living individual, including all plants and animals.
Plant
An organism having cellulose cell walls, growing by synthesis of inorganic substances, generally distinguished by the presence of chlorophyll, and lacking the power of locomotion. Plant parts are included here as well.
Fungus
A eukaryotic organism characterized by the absence of chlorophyll and the presence of a rigid cell wall. Included here are both slime molds and true fungi such as yeasts, molds, mildews, and mushrooms.
Virus
An organism consisting of a core of a single nucleic acid enclosed in a protective coat of protein. A virus may replicate only inside a host living cell. A virus exhibits some but not all of the usual characteristics of living things.
Bacterium
A small, typically one-celled, prokaryotic micro-organism.
Animal
An organism with eukaryotic cells, and lacking stiff cell walls, plastids and photosynthetic pigments.
Vertebrate
An animal which has a spinal column.
Amphibian
A cold-blooded, smooth-skinned vertebrate which characteristically hatches as an aquatic larva, breathing by gills. When mature, the amphibian breathes with lungs.
Bird
A vertebrate having a constant body temperature and characterized by the presence of feathers.
Fish
A cold-blooded aquatic vertebrate characterized by fins and breathing by gills. Included here are fishes having either a bony skeleton, such as a perch, or a cartilaginous skeleton, such as a shark, or those lacking a jaw, such as a lamprey or hagfish.
Reptile
A cold-blooded vertebrate having an external covering of scales or horny plates. Reptiles breathe by means of lungs and are generally egg-laying.
Mammal
A vertebrate having a constant body temperature and characterized by the presence of hair, mammary glands and sweat glands.
Human
Modern man, the only remaining species of the Homo genus.
Anatomical Structure
A normal or pathological part of the anatomy or structural organization of an organism.
Embryonic Structure
An anatomical structure that exists only before the organism is fully formed; in mammals, for example, a structure that exists only prior to the birth of the organism. This structure may be normal or abnormal.
Congenital Abnormality
An abnormal structure, or one that is abnormal in size or location, present at birth or evolving over time as a result of a defect in embryogenesis.
Acquired Abnormality
An abnormal structure, or one that is abnormal in size or location, found in or deriving from a previously normal structure. Acquired abnormalities are distinguished from diseases even though they may result in pathological functioning (e.g., hernias incarcerate).
Fully Formed Anatomical Structure
An anatomical structure in a fully formed organism; in mammals, for example, a structure in the body after the birth of the organism.
Body System
A complex of anatomical structures that performs a common function.
Body Part, Organ, or Organ Component
A collection of cells and tissues which are localized to a specific area or combine and carry out one or more specialized functions of an organism. This ranges from gross structures to small components of complex organs. These structures are relatively localized in comparison to tissues.
Tissue
An aggregation of similarly specialized cells and the associated intercellular substance. Tissues are relatively non-localized in comparison to body parts, organs or organ components.
Cell
The fundamental structural and functional unit of living organisms.
Cell Component
A part of a cell or the intercellular matrix, generally visible by light microscopy.
Gene or Genome
A specific sequence, or in the case of the genome the complete sequence, of nucleotides along a molecule of DNA or RNA (in the case of some viruses) which represent the functional units of heredity.
Body Location or Region
An area, subdivision, or region of the body demarcated for the purpose of topographical description.
Body Space or Junction
An area enclosed or surrounded by body parts or organs or the place where two anatomical structures meet or connect.
Body Substance
Extracellular material, or mixtures of cells and extracellular material, produced, excreted, or accreted by the body. Included here are substances such as saliva, dental enamel, sweat, and gastric acid.
Organism Attribute
A property of the organism or its major parts.
That which is discovered by direct observation or measurement of an organism attribute or condition, including the clinical history of the patient. The history of the presence of a disease is a 'Finding' and is distinguished from the disease itself.
Laboratory or Test Result
The outcome of a specific test to measure an attribute or to determine the presence, absence, or degree of a condition.
Injury or Poisoning
A traumatic wound, injury, or poisoning caused by an external agent or force.
Biologic Function
A state, activity or process of the body or one of its systems or parts.
Physiologic Function
A normal process, activity, or state of the body.
Organism Function
A physiologic function of the organism as a whole, of multiple organ systems, or of multiple organs or tissues.
Mental Process
A physiologic function involving the mind or cognitive processing.
Organ or Tissue Function
A physiologic function of a particular organ, organ system, or tissue.
Cell Function
A physiologic function inherent to cells or cell components.
Molecular Function
A physiologic function occurring at the molecular level.
Genetic Function
Functions of or related to the maintenance, translation or expression of the genetic material.
Pathologic Function
A disordered process, activity, or state of the organism as a whole, of a body system or systems, or of multiple organs or tissues. Included here are normal responses to a negative stimulus as well as patholologic conditions or states that are less specific than a disease. Pathologic functions frequently have systemic effects.
Disease or Syndrome
A condition which alters or interferes with a normal process, state, or activity of an organism. It is usually characterized by the abnormal functioning of one or more of the host's systems, parts, or organs. Included here is a complex of symptoms descriptive of a disorder.
Mental or Behavioral Dysfunction
A clinically significant dysfunction whose major manifestation is behavioral or psychological. These dysfunctions may have identified or presumed biological etiologies or manifestations.
Cell or Molecular Dysfunction
A pathologic function inherent to cells, parts of cells, or molecules.
Experimental Model of Disease
A representation in a non-human organism of a human disease for the purpose of research into its mechanism or treatment.
Event
A broad type for grouping activities, processes and states.
Activity
An operation or series of operations that an organism or machine carries out or participates in.
Behavior
Any of the psycho-social activities of humans or animals that can be observed directly by others or can be made systematically observable by the use of special strategies.
Social Behavior
Behavior that is a direct result or function of the interaction of humans or animals with their fellows. This includes behavior that may be considered anti-social.
Individual Behavior
Behavior exhibited by a human or an animal that is not a direct result of interaction with other members of the species, but which may have an effect on others.
Daily or Recreational Activity
An activity carried out for recreation or exercise, or as part of daily life.
Occupational Activity
An activity carried out as part of an occupation or job.
Health Care Activity
An activity of or relating to the practice of medicine or involving the care of patients.
Laboratory Procedure
A procedure, method, or technique used to determine the composition, quantity, or concentration of a specimen, and which is carried out in a clinical laboratory. Included here are procedures which measure the times and rates of reactions.
A procedure, method, or technique used to determine the nature or identity of a disease or disorder. This excludes procedures which are primarily carried out on specimens in a laboratory.
Therapeutic or Preventive Procedure
A procedure, method, or technique designed to prevent a disease or a disorder, or to improve physical function, or used in the process of treating a disease or injury.
Research Activity
An activity carried out as part of research or experimentation.
Molecular Biology Research Technique
Any of the techniques used in the study of or the directed modification of the gene complement of a living organism.
Governmental or Regulatory Activity
An activity carried out by officially constituted governments, or an activity related to the creation or enforcement of the rules or regulations governing some field of endeavor.
Educational Activity
An activity related to the organization and provision of education.
Machine Activity
An activity carried out primarily or exclusively by machines.
Phenomenon or Process
A process or state which occurs naturally or as a result of an activity.
Human-caused Phenomenon or Process
A phenomenon or process that is a result of the activities of human beings.
Environmental Effect of Humans
A change in the natural environment that is a result of the activities of human beings.
Natural Phenomenon or Process
A phenomenon or process that occurs irrespective of the activities of human beings.
Entity
A broad type for grouping physical and conceptual entities.
Physical Object
An object perceptible to the sense of vision or touch.
Manufactured Object
A physical object made by human beings.
Medical Device
A manufactured object used primarily in the diagnosis, treatment, or prevention of physiologic or anatomic disorders.
Research Device
A manufactured object used primarily in carrying out scientific research or experimentation.
Conceptual Entity
A broad type for grouping abstract entities or concepts.
Idea or Concept
An abstract concept, such as a social, religious or philosophical concept.
Temporal Concept
A concept which pertains to time or duration.
Qualitative Concept
A concept which is an assessment of some quality, rather than a direct measurement.
Quantitative Concept
A concept which involves the dimensions, quantity or capacity of something using some unit of measure, or which involves the quantitative comparison of entities.
Spatial Concept
A location, region, or space, generally having definite boundaries.
Geographic Area
A geographic location, generally having definite boundaries.
Molecular Sequence
A broad type for grouping the collected sequences of amino acids, carbohydrates, and nucleotide sequences. Descriptions of these sequences are generally reported in the published literature and/or are deposited in and maintained by databanks such as GenBank, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Nucleotide Sequence
The sequence of purines and pyrimidines in nucleic acids and polynucleotides. Included here are nucleotide-rich regions, conserved sequence, and DNA transforming region.
Amino Acid Sequence
The sequence of amino acids as arrayed in chains, sheets, etc., within the protein molecule. It is of fundamental importance in determining protein structure.
Carbohydrate Sequence
The sequence of carbohydrates within polysaccharides, glycoproteins, and glycolipids.
Regulation or Law
An intellectual product resulting from legislative or regulatory activity.
Occupation or Discipline
A vocation, academic discipline, or field of study, or a subpart of an occupation or discipline.
Biomedical Occupation or Discipline
A vocation, academic discipline, or field of study related to biomedicine.
Organization
The result of uniting for a common purpose or function. The continued existence of an organization is not dependent on any of its members, its location, or particular facility. Components or subparts of organizations are also included here. Although the names of organizations are sometimes used to refer to the buildings in which they reside, they are not inherently physical in nature.
Health Care Related Organization
An established organization which carries out specific functions related to health care delivery or research in the life sciences.
Professional Society
An organization uniting those who have a common vocation or who are involved with a common field of study.
Self-help or Relief Organization
An organization whose purpose and function is to provide assistance to the needy or to offer support to those sharing similar problems.
Group
A conceptual entity referring to the classification of individuals according to certain shared characteristics.
Professional or Occupational Group
An individual or individuals classified according to their vocation.
Population Group
An indivdual or individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute.
Family Group
An individual or individuals classified according to their family relationships or relative position in the family unit.
Age Group
An individual or individuals classified according to their age.
Patient or Disabled Group
An individual or individuals classified according to a disability, disease, condition or treatment.
Group Attribute
A conceptual entity which refers to the frequency or distribution of certain characteristics or phenomena in certain groups.
Chemical
Compounds or substances of definite molecular composition. Chemicals are viewed from two distinct perspectives in the network, functionally and structurally. Almost every chemical concept is assigned at least two types, generally one from the structure hierarchy and at least one from the function hierarchy.
Chemical Viewed Structurally
A chemical or chemicals viewed from the perspective of their structural characteristics. Included here are concepts which can mean either a salt, an ion, or a compound (e.g., Bromates and Bromides).
Organic Chemical
The general class of carbon-containing compounds, usually based on carbon chains or rings, and also containing hydrogen (hydrocarbons), with or without nitrogen, oxygen, or other elements in which the bonding between elements is generally covalent.
Steroid
One of a group of polycyclic, 17-carbon-atom, fused-ring compounds occurring both in natural and synthetic forms. Included here are naturally occurring and synthetic steroids, bufanolides, cardanolides, homosteroids, norsteroids, and secosteroids.
Eicosanoid
An oxygenated metabolite from polyunsaturated 20 carbon fatty acids including lipoxygenase and cyclooxygenase products and their synthetic analogs. This includes the prostaglandins and thromboxanes.
Nucleic Acid, Nucleoside, or Nucleotide
A complex compound of high molecular weight occurring in living cells. These are basically of two types, ribonucleic (RNA) and deoxyribonucleic (DNA) acids. Nucleic acids are made of nucleotides (nitrogen-containing base, a 5-carbon sugar, and one or more phosphate group) linked together by a phosphodiester bond between the 5' and 3' carbon atoms. Nucleosides are compounds composed of a purine or pyrimidine base (usually adenine, cytosine, guanine, thymine, uracil) linked to either a ribose or a deoxyribose sugar.
Organophosphorus Compound
An organic compound containing phosphorus as a constituent. Included here are organic phosphinic, phosphonic and phosphoric acid derivatives and their thiophosphorus counterparts. Excluded are phospholipids, sugar phosphates, phosphoproteins, nucleotides, and nucleic acids.
Amino Acid, Peptide, or Protein
Amino acids and chains of amino acids connected by peptide linkages.
Carbohydrate
A generic term that includes monosaccharides, oligosaccharides, and polysaccharides as well as substances derived from monosaccharides by reduction of the carbonyl group (alditols), by oxidation of one or more terminal group to carboxylic acids, or by replacement of one or more hydroxy groups by a hydrogen atom, an amino group, a thiol group or similar heteroatomic groups. It also includes derivatives of these compounds. Included here are sugar phosphates. Excluded are glycolipids and glycoproteins.
Lipid
An inclusive group of fat or fat-derived substances that are soluble in nonpolar solvents related to fatty acid esters, fatty alcohols, sterols, waxes, etc. Included in this group are the saponifiable lipids such as glycerides (fats and oils), essential (volatile) oils, and phospholipids.
Chemical Viewed Functionally
A chemical viewed from the perspective of its functional characteristics or pharmacological activities.
Pharmacologic Substance
A substance used in the treatment or prevention of pathologic disorders. This includes substances that occur naturally in the body and are administered therapeutically.
Biomedical or Dental Material
A substance used in biomedicine or dentistry predominantly for its physical, as opposed to chemical, properties. Included here are biocompatible materials, tissue adhesives, bone cements, resins, toothpastes, etc.
Biologically Active Substance
A generally endogenous substance produced or required by an organism, of primary interest because of its role in the biologic functioning of the organism that produces it.
Neuroreactive Substance or Biogenic Amine
An endogenous substance whose activities affect or play an important role in the functioning of the nervous system. Included here are catecholamines, neuroregulators, neurophysins, etc.
Hormone
In animals, a chemical usually secreted by an endocrine gland whose products are released into the circulating fluid. Hormones act as chemical messengers and regulate various physiologic processes such as growth, reproduction, metabolism, etc. They usually fall into two broad classes, steroid hormones and peptide hormones.
Enzyme
A complex chemical, usually a protein, that is produced by living cells and which catalyzes specific biochemical reactions. There are six main types of enzymes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases.
Vitamin
A substance, usually an organic chemical complex, present in natural products or made synthetically, which is essential in the diet of man or other higher animals. Included here are vitamin precursors, provitamins, and vitamin supplements.
Immunologic Factor
A biologically active substance whose activities affect or play a role in the functioning of the immune system.
Indicator, Reagent, or Diagnostic Aid
A substance primarily of interest for its use in laboratory or diagnostic tests and procedures to detect, measure, examine, or analyze other chemicals, processes, or conditions.
Hazardous or Poisonous Substance
A substance of concern because of its potentially hazardous or toxic effects. This would include most drugs of abuse, as well as agents that require special handling because of their toxicity.
Substance
A material with definite or fairly definite chemical composition.
Food
Any substance generally containing nutrients, such as carbohydrates, proteins, and fats, that can be ingested by a living organism and metabolized into energy and body tissue. Some foods are naturally occurring, others are either partially or entirely made by humans.
Functional Concept
A concept which is of interest because it pertains to the carrying out of a process or activity.
Intellectual Product
A conceptual entity resulting from human endeavor. Concepts assigned to this type generally refer to information created by humans for some purpose.
Language
The system of communication used by a particular nation or people.
Sign or Symptom
An observable manifestation of a disease or condition based on clinical judgment, or a manifestation of a disease or condition which is experienced by the patient and reported as a subjective observation.
Classification
A term or system of terms denoting an arrangement by class or category.
Anatomical Abnormality
An abnormal structure, or one that is abnormal in size or location.
Neoplastic Process
A new and abnormal growth of tissue in which the growth is uncontrolled and progressive. The growths may be malignant or benign.
Receptor
A specific structure or site on the cell surface or within its cytoplasm that recognizes and binds with other specific molecules. These include the proteins on the surface of an immunocompetent cell that binds with antigens, or proteins found on the surface molecules that bind with hormones or neurotransmitters and react with other molecules that respond in a specific way.
Archaeon
A member of one of the three domains of life, formerly called Archaebacteria under the taxon Bacteria, but now considered separate and distinct. Archaea are characterized by: 1) the presence of characteristic tRNAs and ribosomal RNAs; 2) the absence of peptidoglycan cell walls; 3) the presence of ether-linked lipids built from branched-chain subunits; and 4) their occurrence in unusual habitats. While archaea resemble bacteria in morphology and genomic organization, they resemble eukarya in their method of genomic replication.
Antibiotic
A pharmacologically active compound produced by growing microorganisms which kill or inhibit growth of other microorganisms.
Element, Ion, or Isotope
One of the 109 presently known fundamental substances that comprise all matter at and above the atomic level. This includes elemental metals, rare gases, and most abundant naturally occurring radioactive elements, as well as the ionic counterparts of elements (NA+, Cl-), and the less abundant isotopic forms. This does not include organic ions such as iodoacetate to which the type 'Organic Chemical' is assigned.
Inorganic Chemical
Chemical elements and their compounds, excluding the hydrocarbons and their derivatives (except carbides, carbonates, cyanides, cyanates and carbon disulfide). Generally inorganic compounds contain ionic bonds. Included here are inorganic acids and salts, alloys, alkalies, and minerals.
Clinical Drug
A pharmaceutical preparation as produced by the manufacturer. The name usually includes the substance, its strength, and the form, but may include the substance and only one of the other two items.
Clinical Attribute
An observable or measurable property or state of an organism of clinical interest.
Drug Delivery Device
A medical device that contains a clinical drug or drugs.
Eukaryote
One of the three domains of life (the others being Bacteria and Archaea), also called Eukarya. These are organisms whose cells are enclosed in membranes and possess a nucleus. They comprise almost all multicellular and many unicellular organisms, and are traditionally divided into groups (sometimes called kingdoms) including Animals, Plants, Fungi, various Algae, and other taxa that were previously part of the old kingdom Protista.
unit
A unit of measurement is a standardized quantity of a physical quality.
length unit
A unit which is a standard measure of the distance between two points.
mass unit
A unit which is a standard measure of the amount of matter/energy of a physical object.
time unit
A unit which is a standard measure of the dimension in which events occur in sequence.
kilogram
A mass unit which is equal to the mass of the International Prototype Kilogram kept by the BIPM at Svres, France.
centimeter
A length unit which is equal to one hundredth of a meter or 10^[-2] m.
day
A time unit which is equal to 24 hours.
month
A time unit which is approximately equal to the length of time of one of cycle of the moon's phases which in science is taken to be equal to 30 days.
year
A time unit which is equal to 12 months which is science is taken to be equal to 365.25 days.
volume unit
A unit which is a standard measure of the amount of space occupied by any substance, whether solid, liquid, or gas.
cubic centimeter
A volume unit which is equal to one millionth of a cubic meter or 10^[-9] m^[3], or to 1 ml.
milliliter
A volume unit which is equal to one thousandth of a liter or 10^[-3] L, or to 1 cubic centimeter.
Liter
radiation unit
A unit which is a standard measure of the amount of radiation emitted by a given radiation source as well as the amount of radiation absorbed or deposited in a specific material by a radiation source.
gray
An absorbed dose unit which is equal to the absorption of one joule of radiation energy by one kilogram of matter.
percent
A dimensionless ratio unit which denotes numbers as fractions of 100.
count unit
A dimensionless unit which denotes a simple count of things.
Interval censored
The event occurred within an interval, but it is not known exactly when. Example: the last measurement day one person was HIV negative and the first measurement day the person was positive are known, but when the seroconversion happened within that interval is not known
Left censored
The event occurred some time before the last measurement, but it is not known exactly when. Example: one person tests HIV positive, but there is no negative test result, so it is not possible to estalish a time interval for seroconversion
Censoring type
Censoring type is a particular type of interval creation. Censoring means that one event prevents another event from being observed (e.g., end of study prevents possible evidence of success or failure from being observed). Though usually employed in the context of time-to-failure, this is not only about time, but it can be about any dimension of interest (e.g., if the measurement is above the maximum value in the scale used, then the measurement is right censored; if it is lower than the minimum detectable, then it is left censored).
Right censored
The event my have occurred some time after the last measurement, but it is not known exactly whether it has, because there are no further observations. Example: one person tests HIV negative at some point, but there are no further observations (e.g., the individual moved, or died), so it is not known whether the person has seroconverted or not
Ninth thoracic vertebra
Tenth thoracic vertebra
Eleventh thoracic vertebra
Twelfth thoracic vertebra
Inferior vena cava
Trunk of systemic vein which is formed by the union of the right common iliac vein and the left common iliac vein and terminates in the right atrium.
Eyeball
Eye Globe
Organ with organ cavity which is connected to the optic nerve. Examples: There are only two eyeballs, the right and the left eyeballs..
Right eyeball
Left eyeball
Atlas
Axis
Third cervical vertebra
Fourth cervical vertebra
Fifth cervical vertebra
Sixth cervical vertebra
Seventh cervical vertebra
Sacral vertebra
Sacrum Vertebrae
Esophageal lymph node
Station 8 N2 lymph node
Station 8 lymph node
First lumbar vertebra
Second lumbar vertebra
Third lumbar vertebra
Fourth lumbar vertebra
Fifth lumbar vertebra
First sacral vertebra
Second sacral vertebra
Third sacral vertebra
Fourth sacral vertebra
Fifth sacral vertebra
Pituitary gland
Pituitary
Supraclavicular lymph node
Colon
Rectum
Wall of rectum
Rectal Wall
Anal canal
Organ with organ cavity which is continuous proximally with the rectum and distally terminates with the anus. Examples: There is only one anal canal.
Internal anal sphincter
Urinary bladder
Organ with organ cavity which is continuous proximally with the right and left ureters and distally with the urethra. Examples: There is only one urinary bladder.
Wall of urinary bladder
Sacrum
Bone complex which has as its direct parts five sacral vertebrae.
Bony pelvis
Pubic symphysis
Uterus
Organ with organ cavity which is continuous proximally with the right and left uterine tubes and distally is connected to the vagina. Examples: There is only one uterus.
Cervix of uterus
Seminal vesicle
Right seminal vesicle
Left seminal vesicle
Bulb of penis
Penile Bulb
Urethra
Organ with organ cavity which connects the cavity of the urinary bladder to the exterior. Examples: There is only one urethra.
Vagina
Organ with organ cavity which connects the cervical canal of uterus to the vestibule of vagina. Examples: There is only one vagina.
Vulva
Parametrium of body of uterus
External anal sphincter
Left supraclavicular lymph node
Right supraclavicular lymph node
Right femur
Left femur
Glenohumeral joint
Glenohumeral Joint
Right glenohumeral joint
Left glenohumeral joint
Bronchial tree
Right bronchial tree
Left bronchial tree
Hippocampus
Right hippocampus
Left hippocampus
Aortopulmonary lymph node
Station 5 N2 lymph node
Station 5 lymph node
Para-aortic thoracic lymph node
Station 6 N2 lymph node
Station 6 lymph node
Interlobar lymph node
Station 11 N1 lymph node
Station 11 lymph node
Lobar lymph node
Station 12 N1 lymph node
Station 12 lymph node
Segmental lymph node
Station 13 N1 lymph node
Station 13 lymph node
Subsegmental lymph node
Station 14 N1 lymph node
Station 14 lymph node
Lymph node of inferior pulmonary ligament
Station 9 N2 lymph node
Station 9 lymph node
Prevertebral lymph node
Station 3P N2 lymph node
Station 3P lymph node
Pre-vascular lymph node
Station 3A N2 lymph node
Station 3A lymph node
Highest mediastinal lymph node
Station 1 N2 lymph node
Station 1 lymph node
Right upper paratracheal lymph node
Right station 2 N2 lymph node
Right station 2 lymph node
Left upper paratracheal lymph node
Left station 2 N2 lymph node
Left station 2 lymph node
Right breast
Left breast
Mesorectal lymph node group
Hip joint
Femoral Joint
Right hip joint
Left hip joint
Aorta
Brachiocephalic artery
Brachiocephalic Artery
Common carotid artery
Right common carotid artery
Subclavian artery
Subclavicular Artery
Systemic artery the trunk of which is continuous with either the trunk of brachiocephalic artery on the right side, or the aorta on the left side.
Right subclavian artery
Subclavian artery the trunk of which is continuous with trunk of brachiocephalic artery.
Left common carotid artery
Right brachial nerve plexus
Left brachial nerve plexus
Constrictor muscle of pharynx
Pharynx
Left subclavian artery
Superior vena cava
Trunk of systemic vein which is formed by the union of the right and left brachiocephalic veins and terminates in the right atrium.
Subclavian vein
SubClavicular Vein
Right subclavian vein
Left subclavian vein
Azygos vein
Masseter
Right masseter
Left masseter
Oral cavity proper
Inferior hypophysial artery
Right inferior hypophyseal artery
Left inferior hypophyseal artery
Superior hypophysial artery
Right superior hypophyseal artery
Left superior hypophyseal artery
Coronary artery
Systemic artery which supplies the heart.
Superior pulmonary vein
Inferior pulmonary vein
Right inferior pulmonary vein
Left inferior pulmonary vein
Right superior pulmonary vein
Left superior pulmonary vein
Right coronary artery
Coronary artery which emerges from the anterior aortic sinus, between the right auricle and the pulmonary trunk, and supplies the right side of the heart.
Left coronary artery
Coronary artery which emerges from the left posterior aortic sinus, between the left auricle and the pulmonary trunk, and supplies the left side of the heart.
Lymph node
Organ component of lymphatic tree organ which has as direct regional parts cortex and medulla.
Brain
Segment of neuraxis which consists of portion of neural tissue organized and subdivided into forebrain, midbrain and hindbrain, contained in cranial cavity and continuous with and rostral to spinal cord.
Optic nerve
Nerve trunk which is continuous with the retina and the optic chiasm.
Oculomotor nerve
Cranial nerve which connects the midbrain to the extra-ocular and intra-ocular muscles.
Trochlear nerve
Trigeminal nerve
Abducens nerve
Facial nerve
Seventh Cranial Nerve
Vestibulocochlear nerve
Eighth Cranial Nerve
Glossopharyngeal nerve
Hypoglossal nerve
Right pulmonary artery
Left pulmonary artery
Right optic nerve
Optic nerve which is continuous with the right retina and the optic chiasm.
Left optic nerve
Optic nerve which is continuous with the left retina and the optic chiasm.
Right facial nerve
Left facial nerve
Right vestibulocochlear nerve
Left vestibulocochlear nerve
Cauda equina
Mandible
External ear
Subdivision of auriculotemporal part of head which has its direct parts pinna and external acoustic tube. Examples: Ther are only two external ears.
Right external ear
Left external ear
Eye
Subdivision of face which has as its direct parts orbital cavity and its content and eyelids.
Right eye
Left eye
Tongue
Posterior part of tongue
Base of tongue
Temporomandibular joint
Temperomandibular Joint
Right temporomandibular joint
Left temporomandibular joint
Submandibular gland
Larynx
Heterogeneous cluster that connects the pharynx to the tracheobronchial tree. Examples: There is only one larynx.
Segment of esophagus
Organ segment which is regional part of esophagus. Examples: cervical part of esophagus, vertebral segment of esophagus.
Glottis
Subdivision of the larynx which consists of the right and left vocal cords and the rima glottidis. Examples: There is only one glottis.
Middle ear
Right middle ear
Left middle ear
Vagus nerve
Cornea
Right cornea
Left cornea
Lens
Eye Lens
Right lens
Left lens
Retina
Layer of wall of eyeball which is continuous with optic nerve.
Right retina
Layer of wall of right eyeball which is continuous with right optic nerve.
Left retina
Layer of wall of left eyeball which is continuous with left optic nerve.
Cranial nerve
Neural tree organ which is continuous with the brain. Examples: Trochlear nerve, facial nerve.
Brachial nerve plexus
Lacrimal gland
Lobular organ the parenchyma of which consists of glandular acini which communicate the lacrimal sac. Examples: There only two, right lacrimal and left lacrimal glands.
Right lacrimal gland
Left lacrimal gland
Right superior tracheobronchial lymph node
Right station 4 N2 lymph node
Right station 4 lymph node
Left superior tracheobronchial lymph node
Left station 4 N2 lymph node
Left station 4 lymph node
Inferior tracheobronchial lymph node
Station 7 N2 lymph node
Station 7 lymph node
Bronchopulmonary lymph node
Station 10 N1 lymph node
Station 10 lymph node
Parotid gland
Parotid
Right parotid gland
Left parotid gland
Right submandibular gland
Left submandibular gland
Lip
Region of labial part of mouth sharing upper or lower boundary of oral orifice.
Cochlea
Right cochlea
Left cochlea
Cerebral hemisphere
Cerebrum
Segment of telencephalon which has as its direct proper parts cerebral cortex and cerebral medulla.
Left cerebral hemisphere
Left cerebral hemisphere is one of two bilateral, largely symmetrical organ subdivisions within the telencephalon which contain the cerebral cortex and cerebral white matter.
Frontal lobe
Frontal lobe is the anterior-most of five lobes of the cerebral hemisphere. It is bounded by the central sulcus on its posterior border and by the longitudinal cerebral fissure on its medial border.
Temporal lobe
Temporal lobe is the ventrolateral lobe of five lobes comprising each cerebral hemisphere. It is bounded dorsally by the lateral fissure and posteriorly by an arbitrary border shared with the occipital lobe.
Parietal lobe
Parietal lobe is the one of five lobes of the cerebral hemisphere which occupies the dorsal-posterior portion of the hemisphere. It is bounded by the central sulcus on its anterior border and and by the longitudinal cerebral fissure on its medial border. Posteriorly it shares an arbitrary border with the occipital lobe.
Hypothalamus
Optic chiasm
Nerve trunk which is continuous with right and left optic nerves and right and left optic tracts.
Blood vessel
Segment of blood vessel tree organ which is a tubular structure the lumen of which contains blood; together with other spatially associated blood vessels constitute blood vessel tree organ.
Pulmonary artery
Pulmonary vein
Vein in the pulmonary vemnous system.
Right cerebral hemisphere
The right cerebral hemisphere is one of two bilateral, largely symmetrical organ subdivisions within the telencephalon which contain the cerebral cortex and cerebral white matter.
Occipital lobe
Occipital lobe is the one of five lobes of the cerebral hemisphere which occupies the posterior-most portion of the hemisphere. Anteriorly, it shares an arbitrary border with the parietal lobe and temporal lobe. Medially, it is bounded by the longitudinal cerebral fissure.
Cerebellum
Segment of neuraxis that has as its parts the cerebellar cortex, cerebellar nuclear complex and cerebellar white matter. Examples: There is only one cerebellum.
Lymph node group
Set of organ components of lymphatic tree organ consisting of lymph nodes without connecting lymphatic vessels.
Heart
Organ with cavitated organ parts, which is continuous with the systemic and pulmonary arterial and venous trees. Examples: There is only one heart.
Right atrium
Right cardiac chamber which is continuous with the superior vena cava and inferior vena cava.
Left atrium
Left cardiac chamber which is continuous with the pulmonary venous trunk.
Right ventricle
Right cardiac chamber which is continuous with the pulmonary arterial trunk.
Cardiac atrium
Cardiac chamber which consists of a wall that surrounds the cavity of an atrium.
Cardiac ventricle
Cardiac chamber which consists of a wall that surrounds the cavity of a ventricle.
Left ventricle
Left cardiac chamber which is continuous with the aorta.
Esophagus
Organ with organ cavity which is continuous superiorly with the pharynx and inferiorly with the stomach. Examples: There is only one esophagus.
Stomach
Organ with organ cavity which is continuous proximally with the esophagus and distally with the small intestine. Examples: There is only one stomach.
Skin
Nonparenchymatous organ that consists of the epidermis, dermis and sets of hair and nails and which surrounds the entire body. Subdivisions of the skin surround various body parts; as a whole, the skin constitutes the external layer of the body. Examples: There is only one skin.
Lung
Lobular organ which has as its parts alveoli connected to the tracheobronchial tree. Examples: There are only two lungs, right lung and left lung.
Spleen
Liver
Lobular organ which has as its parts lobules connected to the biliary tree. Examples: There is only one liver.
Pancreas
Lobular organ the parenchyma of which consists of glandular acini which communicate via a duct system with the duodenum. Examples: There is only one pancreas.
Small intestine
Small Bowel
Organ with organ cavity which is continuous proximally with the stomach and distally with the large intestine. Examples: There is only one small intestine.
Large intestine
Large Bowel
Organ with organ cavity which is continuous proximally with the small intestine and distally with the anal canal. Examples: There is only large intestine.
Kidney
Corticomedullary organ which has as its part renal pelvis shared with and connected to ureter. Examples: There are only two, right kidney and left kidney.
Right kidney
Kidney located right of sagittal midplane of body.
Left kidney
Kidney located left of sagittal midplane of body.
Duodenum
Ovary
Testis
Lobular organ the parenchyma of which consists of seminiferous tubules which communicate with the duct of the epididymis. Examples: There only two, right testis and left testis.
Right testis
Testis located right of sagittal midplane of body.
Left testis
Testis located left of sagittal midplane of body.
Right ovary
Left ovary
Right frontal lobe
Left frontal lobe
Right temporal lobe
Left temporal lobe
Right parietal lobe
Left parietal lobe
Right occipital lobe
Left occipital lobe
Right lung
Lung located right of sagittal midplane of body and which consists of the right upper lobe, middle lobe and right lower lobe.
Left lung
Lung located left of sagittal midplane of body and which consists of the left upper lobe and left lower lobe.
Lobe of lung
Pulmonary hilum
Upper lobe of right lung
Upper lobe of lung
Lower lobe of lung
Lower lobe of right lung
Upper lobe of left lung
Lower lobe of left lung
Middle lobe of right lung
Trachea
Right main bronchus
Left main bronchus
Main bronchus
Lingula of left lung
Right pulmonary hilum
Carina of trachea
Rib cage
Rib
True rib
Typical rib
False rib
Floating rib
Atypical rib
First rib
Second rib
Third rib
Spinal cord
Segment of neuraxis which consists of portion of neural tissue continuous with and caudal to brain, surround central canal and contained in space of vertebral canal.
Fourth rib
Fifth rib
Seventh rib
Right first rib
Right second rib
Right third rib
Right fourth rib
Left first rib
Brainstem
Left second rib
Left third rib
Right fifth rib
Left fifth rib
Eighth rib
Sixth rib
Left fourth rib
Right sixth rib
Left sixth rib
Right seventh rib
Left seventh rib
Right eighth rib
Left eighth rib
Ninth rib
Right ninth rib
Left ninth rib
Tenth rib
Right tenth rib
Left tenth rib
Eleventh rib
Twelfth rib
Right eleventh rib
Left eleventh rib
Right twelfth rib
Left twelfth rib
Thoracic vertebra
First thoracic vertebra
Second thoracic vertebra
Third thoracic vertebra
Fourth thoracic vertebra
Perineum
Subdivision of trunk proper, which is demarcated from the pelvis by the inferior surface of the pelvic diaphragm and from the lower limbs by the perineofemoral lines; together with the thorax, and abdomen, it constitutes the trunk proper. Examples: There is only one perineum.
Salivary gland
Lobular organ the parenchyma of which consists of glandular acini which communicate with oral cavity. Examples: parotid gland, sublingual gland, lingual salivary gland.
Prostate
Lobular organ the parenchyma of which has as its parts glandular acini which are continuous with the prostatic part of the urethra. Examples: There is only one prostate.
Breast
Region of pectoral part of chest which has as its parts nipple, areola, breast proper.
Thyroid gland
Thyroid
Lobular organ the parenchyma of which consists of ductless, glandular follicles filled with colloid. Examples: thyroid gland proper, accessory thyroid gland, lingual thyroid gland.
Femur
Penis
Left pulmonary hilum
Mediastinum
Subdivsion of thoracic compartment which has as its parts the superior mediastinum and inferior mediastinum.
Pericardium
Organ cluster which has as its direct parts the fibrous pericardium and the pericardial sac.
Cervical vertebra
Lumbar vertebra
Fifth thoracic vertebra
Sixth thoracic vertebra
Seventh thoracic vertebra
Eighth thoracic vertebra
InformationEntity
InformationObjectDefinition
An Information Object Definition (IOD) is an object-oriented abstract data model used to specify information about Real-World Objects. An IOD provides communicating Application Entities with a common view of the information to be exchanged. (DICOM)
RTDose
RTImage
RTPlan
RTStructureSet
Series
Two or More Years Survival
Elapsed time two or more years that a person has been alive since a related observation, procedure, event or finding.
Less Than Two Years Survival
Elapsed time is less than two years that a person has been alive since a related observation, procedure, event or finding. The person has died.
Adult comorbidity evaluation-27
The Adult Comorbidity Evaluation - 27 is a 27-item comorbidity index for patients with cancer. It identifies the important medical comorbidities and grades severity using the index. For more information: https://www.rtog.org/LinkClick.aspx?fileticket=xMGEfaLHRuM%3D&tabid=290.
'Age at Diagnosis'
Age at Diagnosis
Age at the time of diagnosis of the disease.
Age at Start RT
The age of the patient at the start of radiotherapy.
GTV (ROI)
A region of interest based on a delineation of the Gross Tumor Volume. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PTV (ROI)
A region of interest based on a delineation of the Planning Target Volume. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SUVmax
The maximum tracer uptake in a given region of interest calculated standardized using the bdy weight and the injected activity.
SUVmean
The mean tracer uptake in a given region of interest calculated standardized using the bdy weight and the injected activity.
Delivered Radiotherapy Total Treatment Dose
The total absorbed radiation dose delivered to a tumor in a complete radiotherapy treatment.
Delivered Radiation Dose
The absorbed radiation dose actually delivered to a tissue.
Prescribed Radiation Dose
The absorbed radiation dose prescribed to be delivered to a tissue.
Survival
Elapsed time that a person has been alive since a related observation, procedure, event or finding.
Sequential Chemoradiotherapy
Chemotherapy given before and/or after radiotherapy.
Living with partner
The social circumstance where a persons lives with a partner in a romantic relantionship.
Cause of death related to cancer
The circumstance or condition that resulted in the death of a living being was related to cancer.
Cause of death directly related to cancer
The circumstance or condition that resulted in the death of a living being was directly related to cancer. An example is death due to respiratory failure cause by metastases in the lung.
Cause of death indirectly related to cancer
The circumstance or condition that resulted in the death of a living being was directly related to cancer. An example is death due to respiratory failure cause by radiation pneuomnitis after lung cancer radiotherapy.
Cause of death not related to cancer
The circumstance or condition that resulted in the death of a living being was not related to cancer.
Positive Lymph Node Stations
Number of positive lymph node stations (PLNS), assessed by FDG-PET scan, using the Naruke map.
Number of Images
The count of images in a given image set.
AJCC Edition
Edition of the American Joint Commission on Cancer (AJCC) Cancer Staging Manual.
AJCC 7th Edition
Seventh edition of the American Joint Commission on Cancer (AJCC) Cancer Staging Manual.
AJCC 6th Edition
Sixth edition of the American Joint Commission on Cancer (AJCC) Cancer Staging Manual.
Volume of the Primary Tumor
The volume of the primary tumor.
Volume of the Positive Macroscopic Nodes
The total volume of all macroscopic lymph nodes metastases in the body.
Radiotherapy Fraction
A therapeutic procedure or session in which part of the full radiotherapy course is delivered. Commonly radiotherapy is given in daily fractions. This allows healthy cells to recover between fractions.
Prescribed Radiotherapy Total Treatment Dose
The total absorbed radiation dose prescribed to a tumor in a complete radiotherapy treatment.
First Radiotherapy fraction
The first fraction of a radiotherapy treatment.
Last Radiotherapy fraction
The last fraction of a radiotherapy treatment.
Person Identifier
An identifier which is used to uniquely identify a person in a certain context (cohort, hospital, trial). Can be a pseudonym.
Living alone
The social circumstance where a persons lives alone.
Survival Time Since First Treatment
Time elapsed between time of fist treatment and the patient's time of death.
Multiple Lobes of the Lung
An area in the body consisting of more than one lung lobe. E.g. a lung cancer may have grown into multiple lobes of the lung.
Non-Thoracic Secondary Neoplasm
A secondary neoplasm which is not found in the thorax.
Thoracic Secondary Neoplasm
A secondary neoplasm which is found in the thorax.
Radiation Oncology Region of Interest
The class of regions of interest used in Radiation Oncology and adhering to the Standardized Naming Conventions in Radiation Oncology.
Target Volume (ROI)
A region of interest based on a delineation of a Target Volume.
Organ at Risk (ROI)
A region of interest based on a delineation of an Organ-At-Risk (OAR).
Concurrent Chemoradiotherapy
Concomitant Chemoradiotheraoy
Chemotherapy administered during radiotherapy.
Radiotherapy Margin
A radiotherapy margin provides a buffer in the delineation of tissues to account for uncertainties. (ICRU 83)
Nonuniform Margin
A radiotherapy margin which is not the same in all directions.
Uniform Margin
A radiotherapy margin which is the same in all directions.
Tumor Length
A one-dimensional size determination of the tumor along the length axis. Typically tumors in elongated organs (e.g. esophagus, rectum) are measured along the long axis of the organ rather than the traverse or other axes.
AnalCanal (ROI)
A region of interest based on a delineation of the anal canal as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Kidney_L (ROI)
A region of interest based on a delineation of the left kidney as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Kidney_R (ROI)
A region of interest based on a delineation of the right kidney as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
MainBronchus_L (ROI)
A region of interest based on a delineation of the left main bronchus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Pulmonary (ROI)
A region of interest based on a delineation of the pulmonary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Carotid (ROI)
A region of interest based on a delineation of the common carotid artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Brachiocephali (ROI)
A region of interest based on a delineation of the brachiocephalic artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Coronary (ROI)
A region of interest based on a delineation of the coronary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Subclavicular (ROI)
A region of interest based on a delineation of the subclavian artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealSuperior (ROI)
A region of interest based on a delineation of the superior hypophysial artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Aorta (ROI)
A region of interest based on a delineation of the aorta as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
AnalSphincter (ROI)
A region of interest based on a delineation of the anal sphincter as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Atrium (ROI)
A region of interest based on a delineation of the cardiac atrium as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Bladder (ROI)
A region of interest based on a delineation of the urinary bladder as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BladderWall (ROI)
A region of interest based on a delineation of the wall of urinary bladder as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BrachialPlexus (ROI)
A region of interest based on a delineation of the brachial nerve plexus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Brain (ROI)
A region of interest based on a delineation of the brain as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BrainStem (ROI)
A region of interest based on a delineation of the brainstem as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Breast (ROI)
A region of interest based on a delineation of the breast as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BronchialTree (ROI)
A region of interest based on a delineation of the bronchial tree as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BaseOfTongue (ROI)
A region of interest based on a delineation of the posterior part of tongue as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Carina (ROI)
A region of interest based on a delineation of the carina of trachea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CaudaEquina (ROI)
A region of interest based on a delineation of the cauda equina as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cerebellum (ROI)
A region of interest based on a delineation of the cerebellum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cerebrum (ROI)
A region of interest based on a delineation of the cerebral hemisphere as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Chiasm (ROI)
A region of interest based on a delineation of the optic chiasm as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VII (ROI)
A region of interest based on a delineation of the facial nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VIII (ROI)
A region of interest based on a delineation of the vestibulocochlear nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cervix (ROI)
A region of interest based on a delineation of the cervix of uterus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cochlea (ROI)
A region of interest based on a delineation of the cochlea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Colon (ROI)
A region of interest based on a delineation of the colon as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
ConstrMuscle (ROI)
A region of interest based on a delineation of the constrictor muscle of pharynx as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cornea (ROI)
A region of interest based on a delineation of the cornea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Duodenum (ROI)
A region of interest based on a delineation of the duodenum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_Middle (ROI)
A region of interest based on a delineation of the middle ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_External (ROI)
A region of interest based on a delineation of the external ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Esophagus (ROI)
A region of interest based on a delineation of the esophagus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Esophagus_Upper (ROI)
A region of interest based on a delineation of the upper third of the esophagus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Esophagus_Lower (ROI)
A region of interest based on a delineation of the lower third of the esophagus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Esophagus_Middle (ROI)
A region of interest based on a delineation of the middle third of the esophagus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
External (ROI)
A region of interest based on a delineation of the skin as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Eye (ROI)
A region of interest based on a delineation of the eye as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Femur (ROI)
A region of interest based on a delineation of the femur as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FemoralJoint (ROI)
A region of interest based on a delineation of the hip joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FrontalLobe (ROI)
A region of interest based on a delineation of the frontal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GHJoint (ROI)
A region of interest based on a delineation of the glenohumeral joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Globe (ROI)
A region of interest based on a delineation of the eyeball as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Glottis (ROI)
A region of interest based on a delineation of the glottis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GreatVessel (ROI)
A region of interest based on a delineation of the great blood vessel as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Heart (ROI)
A region of interest based on a delineation of the heart as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Hippocampus (ROI)
A region of interest based on a delineation of the hippocampus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Hypothalamus (ROI)
A region of interest based on a delineation of the hypothalamus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Kidney (ROI)
A region of interest based on a delineation of the kidney as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
LargeBowel (ROI)
A region of interest based on a delineation of the large intestine as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Larynx (ROI)
A region of interest based on a delineation of the larynx as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
LacrimalGland (ROI)
A region of interest based on a delineation of the lacrimal gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Lens (ROI)
A region of interest based on a delineation of the lens as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Lips (ROI)
A region of interest based on a delineation of the lip as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Liver (ROI)
A region of interest based on a delineation of the liver as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Lung (ROI)
A region of interest based on a delineation of the lung as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Mandible (ROI)
A region of interest based on a delineation of the mandible as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
MassMuscle (ROI)
A region of interest based on a delineation of the masseter as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Mediastinum (ROI)
A region of interest based on a delineation of the mediastinum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
MainBronchus (ROI)
A region of interest based on a delineation of the main bronchus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OccipitalLobe (ROI)
A region of interest based on a delineation of the occipital lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OpticNerve (ROI)
A region of interest based on a delineation of the optic nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OralCavity (ROI)
A region of interest based on a delineation of the oral cavity proper as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ovary (ROI)
A region of interest based on a delineation of the ovary as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Parametrium (ROI)
A region of interest based on a delineation of the parametrium of body of uterus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
ParietalLobe (ROI)
A region of interest based on a delineation of the parietal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Pancreas (ROI)
A region of interest based on a delineation of the pancreas as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Parotid (ROI)
A region of interest based on a delineation of the parotid gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PelvicBones (ROI)
A region of interest based on a delineation of the bony pelvis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PenileBulb (ROI)
A region of interest based on a delineation of the bulb of penis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Penis (ROI)
A region of interest based on a delineation of the penis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Perineum (ROI)
A region of interest based on a delineation of the perineum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Pericardium (ROI)
A region of interest based on a delineation of the pericardium as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Pharynx (ROI)
A region of interest based on a delineation of the pharynx as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PharynxConst (ROI)
Pituitary (ROI)
A region of interest based on a delineation of the pituitary gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Prostate (ROI)
A region of interest based on a delineation of the prostate as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PubicSymphysis (ROI)
A region of interest based on a delineation of the pubic symphysis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rectum (ROI)
A region of interest based on a delineation of the rectum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
RectalWall (ROI)
A region of interest based on a delineation of the wall of rectum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Retina (ROI)
A region of interest based on a delineation of the retina as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib (ROI)
A region of interest based on a delineation of the rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Sacrum (ROI)
A region of interest based on a delineation of the sacrum as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SalivaryGland (ROI)
A region of interest based on a delineation of the salivary gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SeminalVesicle (ROI)
A region of interest based on a delineation of the seminal vesicle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SmallBowel (ROI)
A region of interest based on a delineation of the small intestine as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SpinalCord (ROI)
A region of interest based on a delineation of the spinal cord as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Spleen (ROI)
A region of interest based on a delineation of the spleen as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Stomach (ROI)
A region of interest based on a delineation of the stomach as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Submandibular (ROI)
A region of interest based on a delineation of the submandibular gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Supertentorial (ROI)
A region of interest based on a delineation of the supratentorial brain as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TemporalLobe (ROI)
A region of interest based on a delineation of the temporal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Testis (ROI)
A region of interest based on a delineation of the testis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Thyroid (ROI)
A region of interest based on a delineation of the thyroid gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TMjoint (ROI)
A region of interest based on a delineation of the temporomandibular joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Trachea (ROI)
A region of interest based on a delineation of the trachea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Tongue (ROI)
A region of interest based on a delineation of the tongue as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Urethra (ROI)
A region of interest based on a delineation of the urethra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Uterus (ROI)
A region of interest based on a delineation of the uterus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_Azygos (ROI)
A region of interest based on a delineation of the azygos vein as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_CavaInferior (ROI)
A region of interest based on a delineation of the inferior vena cava as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_CavaSuperior (ROI)
A region of interest based on a delineation of the superior vena cava as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_Pulmonary (ROI)
A region of interest based on a delineation of the pulmonary vein as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_SubClav (ROI)
A region of interest based on a delineation of the subclavian vein as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Vagina (ROI)
A region of interest based on a delineation of the vagina as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_Cervical (ROI)
A region of interest based on a delineation of the cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_Thoracic (ROI)
A region of interest based on a delineation of the thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_Lumbar (ROI)
A region of interest based on a delineation of the lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_Sacrum (ROI)
A region of interest based on a delineation of the sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ventricle (ROI)
A region of interest based on a delineation of the cardiac ventricle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Vessels (ROI)
A region of interest based on a delineation of the blood vessel as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Vulva (ROI)
A region of interest based on a delineation of the vulva as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Living with children
The social circumstance where a persons lives with one of more of their children.
Living with partner and children
The social circumstance where a persons lives with one of more of their children and a partner.
Positive Mediastinal Lymph Node Stations
Number of positive lymph node stations (PLNS), assessed by FDG-PET scan, using the Naruke map using only mediastinal stations (excluding stations 10-14).
Quantity
An abstract concept which is any specification of how many or how much of something there is.
Unimodality Therapy
Use of one treatment modalities; e.g., surgery or radiation or chemotherapy. Can refer to use of two or more chemotherapeutic agents. Can refer to use of two or more radiotherapy modalities (e.g. a combination of brachytherapy and teletherapy).
Lymph Node by Zone and Station
Lymph nodes classified in zones and stations according to lymph node map of the AJCC 7th edition of the TNM classification for lung cancer. For prognostic purposes, thoracic lymph nodes can be divided into prognostic zones which is easier to remember than individual thoracic lymph node stations/levels. For more information see http://dx.doi.org/10.1097/JTO.0b013e3181a0d82e
CTCAE version
Version of the Common Terminology Criteria for Adverse Events (CTCAE) system published by the US National Cancer Institute (NCI).
CTCAE v4.0
Fourth version (published 2009-2010) of the Common Terminology Criteria for Adverse Events (CTCAE) system published by the US National Cancer Institute (NCI).
CTCAE v3.0
Third version (published 2003-2006) of the Common Terminology Criteria for Adverse Events (CTCAE) system published by the US National Cancer Institute (NCI).
CTCAE v2.0
Second version (published 1998-1999) of the Common Terminology Criteria for Adverse Events (CTCAE) system published by the US National Cancer Institute (NCI).
Supraclavicular zone
The supraclavicular zone consists of lymph nodes of nodal station 1.
Aortic Nodes
Artic nodes are lymph nodes in the subaortic or para-aortic zones (nodal stations 5-6).
AP zone
The aortopulmonary zone consists of lymph nodes of nodal stations 5-6.
Patient GUID
Patient UUID
A globally unique identifier identifying a patient.
Superior Mediastinal Nodes
Supoerior mediastinal nodes are lymph nodes in the upper zone (nodal stations 2-4).
DICOM Functional Concept
A concept which is of interest because it pertains to the DICOM protocol. Examples are target and other Information Object Defintion and Entities.
Upper zone
The upper zone consists of lymph nodes of nodal stations 2-4.
D95
Minimum dose to at least 95% of the volume of a target volume or organ at risk. D95 is often reported for target volumes.
D98
Dnear-min
Minimum dose to at least 98% of the volume of a target volume or organ at risk. D98 is often called the near minimum dose.
D50
Dmedian
Median Radiation Dose
Minimum dose to at least 50% of the volume of a target volume or organ at risk. Equivalent to the median dose.
Dnear-max
Minimum dose to at least 2% of the volume of a target volume or organ at risk. D98 is often called the near maximum dose.
Local control time
Elapsed time that a person has been living with/without a related observation/procedure/event/finding of local control/recurrence.
Inferior Mediastinal Nodes
Inferior mediastinal nodes are lymph nodes in the subcarinal or lower zones (nodal stations 7-9).
Distant control time
Elapsed time that a person has been living with/without a related observation/procedure/event/finding of distant control/recurrence.
Subcarinal zone
The subcarinal zone consists of lymph nodes of nodal station 7.
Lower zone
The lower zone consists of lymph nodes of nodal stations 8-9.
N1 nodes
N1 nodes are lymph nodes in the hilar/interlobar or peripheral zones (nodal stations 10-14).
Hilar/interlobar zone
The hilar/interlobar zone consists of lymph nodes of nodal stations 10-11.
Peripheral zone
The peripheral zone consists of lymph nodes of nodal stations 12-14.
Lung_L (ROI)
A region of interest based on a delineation of the left lung as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Lung_R (ROI)
A region of interest based on a delineation of the right lung as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GTVp (ROI)
A region of interest based on a delineation of the Gross Tumor Volume of a primary tumor. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GTVn (ROI)
A region of interest based on a delineation of the Gross Tumor Volume of a metastatic regional node. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Overall Treatment Time - Radiotherapy
Overall treatment time calculated from first until the last day of radiotherapy
Radiation Therapy Alone
A treatment where only radiation is given. This is in contract to e.g. chemoradiotherapy or a combination of surgery and radiation. Can refer to use of two or more radiotherapy modalities (e.g. a combination of brachytherapy and teletherapy).
Parallel-Opposed Fields Radiation Therapy
Parallel opposed fields radiotherapy is a simple form of radiotherapy when using multiple fields. By aiming the two beams along the same axis, the dose fall off in one will be compensated for by the increased dose in the other.
2-Dimensional Radiation Therapy
Two-dimensional (2-D) radiotherapy is a simple form of radiotherapy where treatment planning is based on standardized treatment techniques applied to classes of patients thought to be similar. The process makes use of an X-ray simulator and a 2-D computer treatment planning system used for calculation of dose distributions.
Radiotherapy Total Treatment Dose
TTD
The total absorbed radiation dose prescribed or delivered to a tumor in a complete radiotherapy treatment.
Radiotherapy Fraction Dose
Radiation dose delivered per fraction
Number of Radiotherapy Fractions
The count of radiotherapy fractions given in a certain time interval (e.g. per day) or in a certain coherent context (e.g. per treatment).
Number of Radiotherapy Fractions Per Day
The count of radiotherapy fractions given per day.
Number of Radiotherapy Fractions Per Treatment
The count of radiotherapy fractions given in a radiotherapy treatment as a whole.
Dose Volume Histogram - Dx
Minimum radiation dose to at least x% of the volume.
Dose Volume Histogram - Vx
The percentage volume receiving at least x Gy
V20 of Lung
The percentage of the lung volume (with subtraction of the volume involved by lung cancer) which receives radiation doses of 20 Gy or more.
Radiation Dose From Dose Volume Histogram
A radiation dose quantity derived from a Dose Volume Histogram.
Dmean
Mean Radiation Dose
The mean radiation dose in a given region of interest.
Mean Lung Dose
MLD
The mean radiation dose to the lung as an organ at risk (with subtraction of the volume involved by lung cancer).
Mean Esophagus Dose
The mean radiation dose to the esophagus as an organ at risk.
Maximum Esophagus Dose
The maximum radiation dose to the esophagus as an organ at risk.
Dmax
Maximum Radiation Dose
The mininum radiation dose given to at least 0% of the volume (i.e. to a single point ) of the target volume or organ at risk. Equivalent to the maximum radiation dose.
FEV1 with Medication
The FEV1 measured during bronchodilation and/or steroid use.
Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide
The degree to which inhaled carbon monoxide diffuses from the alveoli into the blood, expressed as a proportion of the predicted normal value.
Acute Radiation Therapy Adverse Event
Early Radiation Therapy Adverse Event
Toxicity from radiation therapy. The critera are relevant from day 1, the commencement of therapy, through day 90. (RTOG definition)
Adverse Event by Time of Onset
Adverse event categorized by the time of onset. Typically adverse events are considered either acute/early or late relative to an intervention.
Late Radiation Therapy Adverse Event
All effects seen after 90 days from the beginning of radiation therapy.
Definitely Related to Cancer
A characteristic used to qualify the adverse event as certainly related to cancer.
Unrelated to Cancer
A characteristic used to qualify the adverse event as clearly not related to cancer.
Unlikely Related to Cancer
A characteristic used to qualify the adverse event as unlikely related to cancer.
Possibly Related to Cancer
A characteristic indicating that an adverse event may be related to cancer.
Probably Related to Cancer
A characteristic used to qualify the adverse event as likely related to cancer.
Probably Related to Pre-existing Comorbidity
A characteristic used to qualify the adverse event as likely related to pre-existing comorbidity.
Possibly Related to Pre-existing Comorbidity
A characteristic indicating that an adverse event may be related to pre-existing comorbidity.
Definitely Related to Pre-existing Comorbidity
A characteristic used to qualify the adverse event as certainly related to pre-existing comorbidity.
Conditionally Related to Pre-existing Comorbidity
A characteristic used to qualify the adverse event as unclassified in term of its relation to pre-existing comorbidity.
Conditionally Related to Cancer
A characteristic used to qualify the adverse event as unclassified in term of its relation to cancer.
Unrelated to Pre-existing Comorbidity
A characteristic used to qualify the adverse event as clearly not related to pre-existing comorbidity.
Unlikely Related to Pre-existing Comorbidity
A characteristic used to qualify the adverse event as unlikely related to pre-existing comorbidity.
Relation to Cancer Unclassifiable
A characteristic used to qualify the adverse event as unclassifiable in term of its relation to cancer.
Relation to Pre-existing Comorbidity Unclassifiable
A characteristic used to qualify the adverse event as unclassifiable in term of its relation to pre-existing comorbidity.
ECOG Performance Status≥2
A performance status which is ECOG 2 or worse.
Never or Former Smoker
A person who was not smoking at the time of consideration and may or may not have smoked in the past.
Both Lobes of the Left Lung
An area in the body consisting of both left lung lobes. E.g. a lung cancer may have grown into both lobes of the left lung.
Minimum of 5 Positive Lymph Node Stations
A count of at least 5 positive lymph node stations assessed by FDG-PET scan.
T0 or T1 Stage Finding
A primary tumor TNM finding indicating that there is either no evidence of primary tumor (T0) or that the cancer is limited to the site of growth (T1).
Medical Contraindication to Concurrent Chemoradiotherapy
A symptom or medical condition that makes a concurrent chemoradiotherapy inadvisable because a person is likely to have a bad reaction.
Equivalent 2Gy Dose
EQD2
Equivalent 2Gy dose: EQD2 = n * d * (d + α/β) / (2 + α/β)
Minimum of 5 Positive Mediastinal Lymph Node Stations
A count of at least 5 positive lymph node stations assessed by FDG-PET scan using only mediastinal stations (excluding stations 10-14).
MainBronchus_R (ROI)
A region of interest based on a delineation of the right main bronchus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Pulmonary_L (ROI)
A region of interest based on a delineation of the left pulmonary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Pulmonary_R (ROI)
A region of interest based on a delineation of the right pulmonary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Carotid_R (ROI)
A region of interest based on a delineation of the right common carotid artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Carotid_L (ROI)
A region of interest based on a delineation of the left common carotid artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Coronary_L (ROI)
A region of interest based on a delineation of the left coronary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Coronary_R (ROI)
A region of interest based on a delineation of the right coronary artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealInferior (ROI)
A region of interest based on a delineation of the inferior hypophysial artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Subclavicular_L (ROI)
A region of interest based on a delineation of the left subclavian artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_Subclavicular_R (ROI)
A region of interest based on a delineation of the right subclavian artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealInferior_L (ROI)
A region of interest based on a delineation of the left inferior hypophyseal artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealInferior_R (ROI)
A region of interest based on a delineation of the right inferior hypophyseal artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealSuperior_L (ROI)
A region of interest based on a delineation of the left superior hypophyseal artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
A_HypophysealSuperior_R (ROI)
A region of interest based on a delineation of the right superior hypophyseal artery as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Atrium_L (ROI)
A region of interest based on a delineation of the left atrium as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Atrium_R (ROI)
A region of interest based on a delineation of the right atrium as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BrachialPlexus_L (ROI)
A region of interest based on a delineation of the left brachial nerve plexus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BrachialPlexus_R (ROI)
A region of interest based on a delineation of the right brachial nerve plexus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Breast_L (ROI)
A region of interest based on a delineation of the left breast as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Breast_R (ROI)
A region of interest based on a delineation of the right breast as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BronchialTree_L (ROI)
A region of interest based on a delineation of the left bronchial tree as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
BronchialTree_R (ROI)
A region of interest based on a delineation of the right bronchial tree as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cerebrum_L (ROI)
A region of interest based on a delineation of the left cerebral hemisphere as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cerebrum_R (ROI)
A region of interest based on a delineation of the right cerebral hemisphere as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VII_L (ROI)
A region of interest based on a delineation of the left facial nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VII_R (ROI)
A region of interest based on a delineation of the right facial nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VIII_L (ROI)
A region of interest based on a delineation of the left vestibulocochlear nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
CN_VIII_R (ROI)
A region of interest based on a delineation of the right vestibulocochlear nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cochlea_L (ROI)
A region of interest based on a delineation of the left cochlea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cochlea_R (ROI)
A region of interest based on a delineation of the right cochlea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cornea_L (ROI)
A region of interest based on a delineation of the left cornea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Cornea_R (ROI)
A region of interest based on a delineation of the right cornea as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_External_L (ROI)
A region of interest based on a delineation of the left external ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_External_R (ROI)
A region of interest based on a delineation of the right external ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_Middle_L (ROI)
A region of interest based on a delineation of the left middle ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ear_Middle_R (ROI)
A region of interest based on a delineation of the right middle ear as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Eye_L (ROI)
A region of interest based on a delineation of the left eye as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Eye_R (ROI)
A region of interest based on a delineation of the right eye as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FemoralJoint_L (ROI)
A region of interest based on a delineation of the left hip joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FemoralJoint_R (ROI)
A region of interest based on a delineation of the right hip joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Femur_L (ROI)
A region of interest based on a delineation of the left femur as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Femur_R (ROI)
A region of interest based on a delineation of the right femur as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FrontalLobe_L (ROI)
A region of interest based on a delineation of the left frontal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
FrontalLobe_R (ROI)
A region of interest based on a delineation of the right frontal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GHJoint_L (ROI)
A region of interest based on a delineation of the left glenohumeral joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
GHJoint_R (ROI)
A region of interest based on a delineation of the right glenohumeral joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Globe_L (ROI)
A region of interest based on a delineation of the left eyeball as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Globe_R (ROI)
A region of interest based on a delineation of the right eyeball as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Hippocampus_L (ROI)
A region of interest based on a delineation of the left hippocampus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Hippocampus_R (ROI)
A region of interest based on a delineation of the right hippocampus as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
MassMuscle_L (ROI)
A region of interest based on a delineation of the left masseter as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
MassMuscle_R (ROI)
A region of interest based on a delineation of the right masseter as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OccipitalLobe_L (ROI)
A region of interest based on a delineation of the left occipital lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OccipitalLobe_R (ROI)
A region of interest based on a delineation of the right occipital lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OpticNerve_L (ROI)
A region of interest based on a delineation of the left optic nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
OpticNerve_R (ROI)
A region of interest based on a delineation of the right optic nerve as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ovary_L (ROI)
A region of interest based on a delineation of the left ovary as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ovary_R (ROI)
A region of interest based on a delineation of the right ovary as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
ParietalLobe_L (ROI)
A region of interest based on a delineation of the left parietal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
ParietalLobe_R (ROI)
A region of interest based on a delineation of the right parietal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Parotid_L (ROI)
A region of interest based on a delineation of the left parotid gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Parotid_R (ROI)
A region of interest based on a delineation of the right parotid gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Retina_L (ROI)
A region of interest based on a delineation of the left retina as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Retina_R (ROI)
Rib1_L (ROI)
A region of interest based on a delineation of the left first rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib2_L (ROI)
A region of interest based on a delineation of the left second rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib3_L (ROI)
A region of interest based on a delineation of the left third rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib4_L (ROI)
A region of interest based on a delineation of the left fourth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib5_L (ROI)
A region of interest based on a delineation of the left fifth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib6_L (ROI)
A region of interest based on a delineation of the left sixth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib7_L (ROI)
A region of interest based on a delineation of the left seventh rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib8_L (ROI)
A region of interest based on a delineation of the left eighth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib9_L (ROI)
A region of interest based on a delineation of the left ninth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib10_L (ROI)
A region of interest based on a delineation of the left tenth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib11_L (ROI)
A region of interest based on a delineation of the left eleventh rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib12_L (ROI)
A region of interest based on a delineation of the left twelfth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib12_R (ROI)
A region of interest based on a delineation of the right twelfth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib11_R (ROI)
A region of interest based on a delineation of the right eleventh rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib10_R (ROI)
A region of interest based on a delineation of the right tenth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib9_R (ROI)
A region of interest based on a delineation of the right ninth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib8_R (ROI)
A region of interest based on a delineation of the right eighth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib7_R (ROI)
A region of interest based on a delineation of the right seventh rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib6_R (ROI)
A region of interest based on a delineation of the right sixth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib5_R (ROI)
A region of interest based on a delineation of the right fifth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib4_R (ROI)
A region of interest based on a delineation of the right fourth rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib3_R (ROI)
A region of interest based on a delineation of the right third rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib2_R (ROI)
A region of interest based on a delineation of the right second rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Rib1_R (ROI)
A region of interest based on a delineation of the right first rib as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SeminalVesicle_L (ROI)
A region of interest based on a delineation of the left seminal vesicle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
SeminalVesicle_R (ROI)
A region of interest based on a delineation of the right seminal vesicle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Submandibular_L (ROI)
A region of interest based on a delineation of the left submandibular gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Submandibular_R (ROI)
A region of interest based on a delineation of the right submandibular gland as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TemporalLobe_L (ROI)
A region of interest based on a delineation of the left temporal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TemporalLobe_R (ROI)
A region of interest based on a delineation of the right temporal lobe as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Testis_L (ROI)
A region of interest based on a delineation of the left testis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Testis_R (ROI)
A region of interest based on a delineation of the right testis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TMjoint_L (ROI)
A region of interest based on a delineation of the left temporomandibular joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
TMjoint_R (ROI)
A region of interest based on a delineation of the right temporomandibular joint as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_SubClav_L (ROI)
A region of interest based on a delineation of the left subclavian vein as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
V_SubClav_R (ROI)
A region of interest based on a delineation of the right subclavian vein as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C1 (ROI)
A region of interest based on a delineation of the atlas as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C2 (ROI)
A region of interest based on a delineation of the axis as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C3 (ROI)
A region of interest based on a delineation of the third cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C4 (ROI)
A region of interest based on a delineation of the fourth cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C5 (ROI)
A region of interest based on a delineation of the fifth cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C6 (ROI)
A region of interest based on a delineation of the sixth cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_C7 (ROI)
A region of interest based on a delineation of the seventh cervical vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_L1 (ROI)
A region of interest based on a delineation of the first lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_L2 (ROI)
A region of interest based on a delineation of the second lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_L3 (ROI)
A region of interest based on a delineation of the third lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_L4 (ROI)
A region of interest based on a delineation of the fourth lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_L5 (ROI)
A region of interest based on a delineation of the fifth lumbar vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_S1 (ROI)
A region of interest based on a delineation of the first sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_S2 (ROI)
A region of interest based on a delineation of the second sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_S3 (ROI)
A region of interest based on a delineation of the third sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_S4 (ROI)
A region of interest based on a delineation of the fourth sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_S5 (ROI)
A region of interest based on a delineation of the fifth sacral vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T1 (ROI)
A region of interest based on a delineation of the first thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T2 (ROI)
A region of interest based on a delineation of the second thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T3 (ROI)
A region of interest based on a delineation of the third thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T4 (ROI)
A region of interest based on a delineation of the fourth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T5 (ROI)
A region of interest based on a delineation of the fifth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T6 (ROI)
A region of interest based on a delineation of the sixth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T7 (ROI)
A region of interest based on a delineation of the seventh thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T8 (ROI)
A region of interest based on a delineation of the eighth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T9 (ROI)
A region of interest based on a delineation of the ninth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T10 (ROI)
A region of interest based on a delineation of the tenth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T11 (ROI)
A region of interest based on a delineation of the eleventh thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
VB_T12 (ROI)
A region of interest based on a delineation of the twelfth thoracic vertebra as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ventricle_L (ROI)
A region of interest based on a delineation of the left ventricle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Ventricle_R (ROI)
A region of interest based on a delineation of the right ventricle as an organ at risk in radiation oncology. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Gross Tumor Volume - Metastasis
The gross tumor volume of a distant metastasis of a tumor.
CTV (ROI)
A region of interest based on a delineation of the Clinical Target Volume. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Clinical Target Volume - Node
The clinical target volume of a metastatic regional node of a tumor.
Clinical Target Volume - Primary Tumor
The clinical target volume of a primary tumor.
ITV (ROI)
A region of interest based on a delineation of the Internal Target Volume.
PRV (ROI)
A region of interest based on a delineation of a Planning Organ at Risk Volume (PRV). The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Radiation Oncology Functional Concept
A concept which is of interest because it pertains to the carrying out of radiation oncology. Examples are target and other irradiated volumes, margins etc.
Gross Tumor Volume
The Gross Tumor Volume (GTV) is the gross demonstrable extent and location of the tumor. The GTV may consist of a primary tumor (primary tumor GTV or GTV-T), metastatic regional node(s) (nodal GTV or GTV-N), or distant metastasis (metastatic GTV, or GTV-M). Typically, different GTVs are defined for the primary tumor and the regional node(s). But in some particular clinical situations, it might well be that the metastatic node cannot be distinguished from the primary tumor, e.g., a nasopharyngeal undifferentiated carcinoma infiltrating posterolaterally into the retropharyngeal space, including possible infiltrated nodes. In such situations, a single GTV encompassing both the primary tumor and the node(s) may be delineated. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
Internal Target Volume
In ICRU Report 62 (ICRU, 1999), the Internal Target Volume (ITV) was defined as the CTV plus a margin taking into account uncertainties in size, shape, and position of the CTV within the patient. Such a margin was called the internal margin as opposed to the set-up margin. In ICRU Report 62, it was recommended that internal and external margins be added quadratically, but often in practice they are instead added linearly, which can lead to an unacceptably large margin. The ITV might be useful only in clinical situations in which uncertainty concerning the CTV location dominates setup uncertainties and/or when they are independent. The ITV is considered an optional tool in helping to delineate the PTV. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
Planning Target Volume
The Planning Target Volume (PTV) is a geometrical concept introduced for treatment planning and evaluation. It is the recommended tool to shape absorbed-dose distributions to ensure that the prescribed absorbed dose will actually be delivered to all parts of the CTV with a clinically acceptable probability, despite geometrical uncertainties such as organ motion and setup variations. It is also used for absorbed-dose prescription and reporting. It surrounds the representation of the CTV with a margin such that the planned absorbed dose is delivered to the CTV. This margin takes into account both the internal and the setup uncertainties. The setup margin accounts specifically for uncertainties in patient positioning and alignment of the therapeutic beams during the treatment planning, and through all treatment sessions. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
Clinical Target Volume
The Clinical Target Volume (CTV) is a volume of tissue that contains a demonstrable GTV and/or subclinical malignant disease with a certain probability of occurrence considered relevant for therapy. There is no general consensus on what probability is considered relevant for therapy, but typically a probability of occult disease higher than from 5 % to 10 % is assumed to require treatment. This remains a clinical judgment in which the type of malignancy, the consequence of failure, and the expected feasibility of salvage treatment need to be considered. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
CTVn (ROI)
A region of interest based on a delineation of the Clinical Target Volume of a metastatic regional node. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Clinical Target Volume - Metastasis
The clinical target volume of a distant metasasis of a tumor.
CTVp (ROI)
A region of interest based on a delineation of the Clinical Target Volume of a primary tumor. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Gross Tumor Volume - Node
The gross tumor volume of a metastatic regional node of a tumor.
Gross Tumor Volume - Primary Tumor
The gross tumor volume of a primary tumor.
Target Volume
A Target Volume is a volume of tissue or of a geometrical concept forming the target for irradiation during radiation oncology.
Planning Organ at Risk Volume
The Planning Organ at Risk Volume (PRV) is a geometrical concept introduced for treatment planning and evaluation. It surrounds the representation of the Organ at Risk (OAR) with a margin. This margin takes into account both the internal and the setup uncertainties. The setup margin accounts specifically for uncertainties in patient positioning and alignment of the therapeutic beams during the treatment planning, and through all treatment sessions. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
Organ at Risk
The Organ-At-Risk (OAR) or critical normal structures are tissues that if irradiated could suffer significant morbidity and thus might influence the treatment planning and/or the absorbed-dose prescription. (ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
PTVn (ROI)
A region of interest based on a delineation of the Planning Target Volume of a metastatic regional node. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
PTVp (ROI)
A region of interest based on a delineation of the Planning Target Volume of a primary tumor. The label adheres to the standardized naming convention proposed by Santanam et al (http://dx.doi.org/10.1016/j.ijrobp.2011.09.054).
Planning Target Volume - Metastasis
The Planning Target Volume of a distant metasasis of a tumor.
Planning Target Volume - Node
The Planning Target Volume of a metastatic regional node of a tumor.
Planning Target Volume - Primary Tumor
The Planning Target Volume of a primary tumor.
Treated Volume
The TV is the volume of tissue enclosed within a specific isodose envelope, with the absorbed dose specified by the radiation oncology team as appropriate to achieve tumor eradication or palliation, within the bounds of acceptable complications. As proposed in proton therapy (ICRU, 2007), D98% could be selected to determine the TV in photon therapy. When reported, the value of the isodose selected to define the TV should be quoted either relative to the prescribed absorbed dose or in absolute terms. It is important to identify the shape, size, and position of the TV in relation to the PTV for several reasons. One reason is to provide information to evaluate causes for local recurrences (inside or outside the TV).(ICRU 83) For more information: http://dx.doi.org/10.1093/jicru/ndq001
Metabolic Tumor Volume
Metabolic tumor volume (MTV) is the volume of tumor tissues with increased FDG uptake measured by an 18F-FDG PET scan.
FUMIR Regimen
Regimen combining Mitomycin and Fluorouracil (with concurrent radiation)
Tumor Regression Grade - Dworak
Tumor regression grade according to the Dworak system.
Tumor Regression Grade - Mandard
Tumor regression grade according to the Mandard system.
TRG1 - Mandard
Complete Regression
Near Complete Regression
Moderate Regression
Minimal Regression
No Regression
TRG2 - Mandard
TRG3 - Mandard
TRG4 - Mandard
TRG5 - Mandard
TRG0 - Dworak
TRG1 - Dworak
TRG2 - Dworak
TRG3 - Dworak
TRG4 - Dworak
Motion Management Procedure
A procedure in which internal motion is managed of organs and/or regions of interest (e.g. tumors) during radiotherapy or imaging or another therapeutic or imaging procedure. This management can be implicit in the procedure (e.g. 4D-CT) are added to any procedure (e.g. breath hold). The motion can be due to respiration, circulation, peristalsis, swallowing, etc. Both procedures to prevent motion (e.g. breath hold) and/or deal with motion (e.g. gating) are part of this class of concepts. Not meant here are procedures meant to deal with the overal motion of the patient (e.g immobilisation).
Deep Inspiration Breath-Hold
DIBH
Deep Inspiration Breath-Hold is mostly used in radiotherapy and involves the patient inspiring to a specified threshold and then holding that level of inspiration during the delivery of radiation.
Breathing Modification Procedure
A class of procedures where respiratory motion is managed by patients temporarily changing the way they breath, either forced or voluntary and for either therapeutic or diagnostic procedures.
Abdominal Compression
A procedure which compresses the abdomen and thereby forcing the patient to use shallow breathing. This in turn reduces the motion associated with respiration.
Respiratory Gated Radiation Therapy
In respiratory gated radiation therapy the beam is switched on when the tumor is in the right phase of the respiration.
Tumor Tracking Radiation Therapy
In tumor tracking radiation therapy the beam is always on and follows the tumor during respiration. It often involves implanting fiducial markers into the tumor.
Partial Mesorectal Excision
PME
Surgical procedure for rectosigmoid and upper rectal cancers where the rectum is transected 5 cm below the tumor.
Unilateral Lymph Node Dissection
Lymph node dissection on only one side of regional lymph nodes. This is usually done when the tumor is located on that side of the body.
Bilateral Lymph Node Dissection
Lymph node dissection on both sides of regional lymph nodes. This is usually done when the tumor is centrally located .
Extra mesorectal lymph node group
Anal sphincter
Either of two sphincters controlling the closing of the anus: a : an outer sphincter of striated muscle extending from the coccyx to the central tendinous part of the perineum and surrounding the anus immediately beneath the skin—called also external anal sphincter, sphincter ani externus b : an inner sphincter formed by thickening of the circular smooth muscle of the rectum—called also internal anal sphincter, sphincter ani internus pecify internal or external.